Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
<,18987624,I]/IC(50),"[I]/IC(50) < 0.1 shows high false-negative rates (24% AUC, 41% C(max)); however, to a limited extent, [I(2)]/IC(50) < 10 is predictive of negative digoxin interaction for AUC, and [I]/IC(50) > 0.1 is predictive of clinical digoxin interactions (AUC and C(max)).",Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18987624/),,0.1,1394,DB01118,Amiodarone
<,18987624,I(2)]/IC(50),"[I]/IC(50) < 0.1 shows high false-negative rates (24% AUC, 41% C(max)); however, to a limited extent, [I(2)]/IC(50) < 10 is predictive of negative digoxin interaction for AUC, and [I]/IC(50) > 0.1 is predictive of clinical digoxin interactions (AUC and C(max)).",Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18987624/),,10,1395,DB01118,Amiodarone
>,18987624,I]/IC(50),"[I]/IC(50) < 0.1 shows high false-negative rates (24% AUC, 41% C(max)); however, to a limited extent, [I(2)]/IC(50) < 10 is predictive of negative digoxin interaction for AUC, and [I]/IC(50) > 0.1 is predictive of clinical digoxin interactions (AUC and C(max)).",Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18987624/),,0.1,1396,DB01118,Amiodarone
,32915088,AUCinf,"Pharmacokinetic exposure (AUCinf = 1472 ng·h/mL) associated with administration of 10 mg/kg of dronedarone increased significantly, with delayed T max in the group that received ticagrelor-pretreatment when compared to the dronedarone only group (AUCinf = 723 ng·h/mL).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],1472,5817,DB01118,Amiodarone
,32915088,AUCinf,"Pharmacokinetic exposure (AUCinf = 1472 ng·h/mL) associated with administration of 10 mg/kg of dronedarone increased significantly, with delayed T max in the group that received ticagrelor-pretreatment when compared to the dronedarone only group (AUCinf = 723 ng·h/mL).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],723,5818,DB01118,Amiodarone
,32915088,AUCinf,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],2391,5819,DB01118,Amiodarone
,32915088,K el,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),1/[h],0.31,5820,DB01118,Amiodarone
,32915088,V z/F,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[l] / [kg],14.6,5821,DB01118,Amiodarone
,32915088,AUCinf,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],1616,5822,DB01118,Amiodarone
,32915088,K el,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),1/[h],0.21,5823,DB01118,Amiodarone
,32915088,V z/F,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[l] / [kg],31.3,5824,DB01118,Amiodarone
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.75,10331,DB01118,Amiodarone
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.36,10332,DB01118,Amiodarone
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.107,10333,DB01118,Amiodarone
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.074,10334,DB01118,Amiodarone
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,32.0,10335,DB01118,Amiodarone
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,49.2,10336,DB01118,Amiodarone
,19591121,flow-rate,The analysis was performed on a C(8) column 3.5 microm (2.1 x 50 mm) heated to 60 degrees C with a mobile phase consisting of acetonitrile:methanol:0.2% NH(4)OH (60:20:20) at an isocratic flow-rate of 0.2 mL/min.,An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),[ml] / [min],0.2,12523,DB01118,Amiodarone
,19591121,m/,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),,1202.8,12524,DB01118,Amiodarone
,19591121,m/,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),,645.9,12525,DB01118,Amiodarone
,19591121,retention times,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),min,3.35,12526,DB01118,Amiodarone
,19591121,retention times,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),min,4.72,12527,DB01118,Amiodarone
greater,3078155,volume of distribution,It is apparent that wide gaps still exist in our knowledge of amiodarone's pharmacokinetics in humans and the best fit for the observations following a single oral dose and chronic dosing is that of a three compartment model with body tissues acting as a large reservoir of the drug; hence the very large volume of distribution (greater than 5001).,Clinical pharmacokinetics of amiodarone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3078155/),,500,13017,DB01118,Amiodarone
,3078155,bioavailability,The drug's bioavailability is modest (approximately 40%) and excretion is minimal via the hepatic route.,Clinical pharmacokinetics of amiodarone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3078155/),%,40,13018,DB01118,Amiodarone
,31898152,peak plasma concentrations,"Poyendarone hydrochloride in doses of 0.3 and 3 mg/kg over 30 s was intravenously administered to the halothane-anesthetized dogs (n = 4), which provided peak plasma concentrations of 108 ± 10 and 1120 ± 285 ng/mL, respectively.","How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31898152/),[ng] / [ml],108,13998,DB01118,Amiodarone
,31898152,peak plasma concentrations,"Poyendarone hydrochloride in doses of 0.3 and 3 mg/kg over 30 s was intravenously administered to the halothane-anesthetized dogs (n = 4), which provided peak plasma concentrations of 108 ± 10 and 1120 ± 285 ng/mL, respectively.","How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31898152/),[ng] / [ml],1120,13999,DB01118,Amiodarone
,2384884,terminal half-life,Three exponential terms were sufficient to describe the plasma concentration-time curve of unchanged AM with a long terminal half-life of 131 hr.,"Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384884/),h,131,15792,DB01118,Amiodarone
,3820092,terminal half-lives (t1/2 gamma),The blood amiodarone concentration-time curves for the four doses were best described by a triexponential equation with terminal half-lives (t1/2 gamma) ranging from 17 to 20 hr.,Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3820092/),h,17 to 20,15885,DB01118,Amiodarone
,3820092,central,"Over the dose range studied, no changes in gamma, t1/2 gamma, or central compartment volume (Vc = 1.2-1.4 L/kg) were observed.",Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3820092/),[l] / [kg],1.2-1.4,15886,DB01118,Amiodarone
,3820092,clearance (CL),"On the other hand, reductions in amiodarone clearance (CL) and steady-state volume of distribution (Vss) of 44% (17.7 to 10.0 ml/min per kg) and 50% (16.4 to 8.2 L/kg), respectively, were noted as the dose of amiodarone increased.",Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3820092/),[ml] / [kg·min],17.7 to 10.0,15887,DB01118,Amiodarone
,3964797,systemic clearance,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).",Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],234,16923,DB01118,Amiodarone
,3964797,systemic clearance,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).",Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],172,16924,DB01118,Amiodarone
,3964797,renal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],105,16925,DB01118,Amiodarone
,3964797,renal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],84,16926,DB01118,Amiodarone
,3964797,nonrenal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],130,16927,DB01118,Amiodarone
,3964797,nonrenal clearance,This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),[ml] / [min],88,16928,DB01118,Amiodarone
,3964797,half-life of elimination,Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),h,34,16929,DB01118,Amiodarone
,3964797,half-life of elimination,Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05).,Pharmacokinetic evaluation of the digoxin-amiodarone interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964797/),h,40,16930,DB01118,Amiodarone
,16616880,limit of quantification (LOQ),"The limit of quantification (LOQ) was set at 50 and 5 ng ml(-1) for the HPLC-UV method and the LC-MS/MS method, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],50,19421,DB01118,Amiodarone
,16616880,limit of quantification (LOQ),"The limit of quantification (LOQ) was set at 50 and 5 ng ml(-1) for the HPLC-UV method and the LC-MS/MS method, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],5,19422,DB01118,Amiodarone
,16616880,limit of detection (LOD),"For the UV method, the limit of detection (LOD) was 15 and 10 ng ml(-1) for amiodarone and desethylamiodarone, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],15,19423,DB01118,Amiodarone
,16616880,limit of detection (LOD),"For the UV method, the limit of detection (LOD) was 15 and 10 ng ml(-1) for amiodarone and desethylamiodarone, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],10,19424,DB01118,Amiodarone
,16616880,LODs,"The LODs of the LC-MS/MS method in plasma were much lower, i.e. 0.10 and 0.04 ng ml(-1) for amiodarone and desethylamiodarone, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],0.10,19425,DB01118,Amiodarone
,16616880,LODs,"The LODs of the LC-MS/MS method in plasma were much lower, i.e. 0.10 and 0.04 ng ml(-1) for amiodarone and desethylamiodarone, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],0.04,19426,DB01118,Amiodarone
,16616880,LODs,"The LODs obtained for the urine samples were 0.16 and 0.09 ng ml(-1) for amiodarone and desethylamiodarone, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],0.16,19427,DB01118,Amiodarone
,16616880,LODs,"The LODs obtained for the urine samples were 0.16 and 0.09 ng ml(-1) for amiodarone and desethylamiodarone, respectively.",Determination of amiodarone and desethylamiodarone in horse plasma and urine by high-performance liquid chromatography combined with UV detection and electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616880/),[ng] / [ml],0.09,19428,DB01118,Amiodarone
,3708866,plasma clearance,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[ml] / [d·kg],64,23422,DB01118,Amiodarone
,3708866,plasma clearance,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[ml] / [d·kg],109,23423,DB01118,Amiodarone
,3708866,production rate,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[nM] / [d·kg],3.8,23424,DB01118,Amiodarone
,3708866,production rate,"The plasma clearance of T4 in rabbits treated with amiodarone for 6 weeks was significantly reduced relative to controls (64 +/- 25 vs 109 +/- 19 ml/kg per day, P less than 0.01) but the production rate was unchanged (3.8 +/- 1.8 vs 3.7 +/- 1.4 nmol/kg per day).",The effect of amiodarone on thyroxine kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708866/),[nM] / [d·kg],3.7,23425,DB01118,Amiodarone
,7083508,indirect,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,35,24046,DB01118,Amiodarone
,7083508,therapeutic half-life,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,25 to 55,24047,DB01118,Amiodarone
,7083508,therapeutic half-life,"The indirect therapeutic half-life of amiodarone in seven patients, computed from the semilogarithmic plots of plasma rT3 after cessation of amiodarone therapy, ranged from 25 to 55 days (mean 35 days).",Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083508/),d,35,24048,DB01118,Amiodarone
,11554436,terminal half-life,The elimination of amiodarone from plasma after single dose followed a biphasic pattern with a terminal half-life of 54.7+/-8.2 hours.,Disposition of amiodarone in rats after single and multiple intraperitoneal doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554436/),h,54.7,29724,DB01118,Amiodarone
,11554436,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 microg/ml, 1.73 microg/mg and 29.01 microg/mg, respectivelly.",Disposition of amiodarone in rats after single and multiple intraperitoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554436/),[μg] / [mg],1.73,29725,DB01118,Amiodarone
,11554436,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 microg/ml, 1.73 microg/mg and 29.01 microg/mg, respectivelly.",Disposition of amiodarone in rats after single and multiple intraperitoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554436/),[μg] / [mg],29.01,29726,DB01118,Amiodarone
,11554436,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat during multiple doses were 0.97 microg/ml, 1.41 microg/mg, 7.63 microg/mg and 65.01 microg/mg respectively.",Disposition of amiodarone in rats after single and multiple intraperitoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554436/),[μg] / [mg],1.41,29727,DB01118,Amiodarone
,11554436,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat during multiple doses were 0.97 microg/ml, 1.41 microg/mg, 7.63 microg/mg and 65.01 microg/mg respectively.",Disposition of amiodarone in rats after single and multiple intraperitoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554436/),[μg] / [mg],7.63,29728,DB01118,Amiodarone
,11554436,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat during multiple doses were 0.97 microg/ml, 1.41 microg/mg, 7.63 microg/mg and 65.01 microg/mg respectively.",Disposition of amiodarone in rats after single and multiple intraperitoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554436/),[μg] / [mg],65.01,29729,DB01118,Amiodarone
,11179527,time (tmax) to Cmax,"Food also significantly increased the rate of absorption, reducing the time (tmax) to Cmax from 7.1 to 4.5 hours.",Bioavailability of amiodarone tablets administered with and without food in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11179527/),h,7.1,33030,DB01118,Amiodarone
,11179527,time (tmax) to Cmax,"Food also significantly increased the rate of absorption, reducing the time (tmax) to Cmax from 7.1 to 4.5 hours.",Bioavailability of amiodarone tablets administered with and without food in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11179527/),h,4.5,33031,DB01118,Amiodarone
,17221913,m/z,"The concentrations of ethopropazine (internal standard), desethylamiodarone and amiodarone were monitored for m/z of 313.10, combination of 546.9 and 617.73, and 645.83, respectively.",A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221913/),,313.10,37699,DB01118,Amiodarone
,17221913,m/z,"The concentrations of ethopropazine (internal standard), desethylamiodarone and amiodarone were monitored for m/z of 313.10, combination of 546.9 and 617.73, and 645.83, respectively.",A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221913/),,546.9,37700,DB01118,Amiodarone
,17221913,m/z,"The concentrations of ethopropazine (internal standard), desethylamiodarone and amiodarone were monitored for m/z of 313.10, combination of 546.9 and 617.73, and 645.83, respectively.",A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221913/),,617.73,37701,DB01118,Amiodarone
,17221913,m/z,"The concentrations of ethopropazine (internal standard), desethylamiodarone and amiodarone were monitored for m/z of 313.10, combination of 546.9 and 617.73, and 645.83, respectively.",A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221913/),,645.83,37702,DB01118,Amiodarone
,4092724,serum elimination half-life,The serum elimination half-life of NANDAI of 57-160 days exceeded that of amiodarone (35-68 days) and of desethylamiodarone (31-110 days).,"Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4092724/),d,57-160,38459,DB01118,Amiodarone
,4092724,serum elimination half-life,The serum elimination half-life of NANDAI of 57-160 days exceeded that of amiodarone (35-68 days) and of desethylamiodarone (31-110 days).,"Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4092724/),d,35-68,38460,DB01118,Amiodarone
,4092724,serum elimination half-life,The serum elimination half-life of NANDAI of 57-160 days exceeded that of amiodarone (35-68 days) and of desethylamiodarone (31-110 days).,"Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4092724/),d,31-110,38461,DB01118,Amiodarone
,4092724,Km,"At steady state the serum concentration of desethylamiodarone appears to be related to the concentration of amiodarone by a Michaelis-Menten type function, yielding a Km of amiodarone of 2.45 mumol/l and a maximal desethylamiodarone concentration of 3.61 mumol/l.","Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4092724/),[μM] / [l],2.45,38462,DB01118,Amiodarone
,4092724,maximal desethylamiodarone concentration,"At steady state the serum concentration of desethylamiodarone appears to be related to the concentration of amiodarone by a Michaelis-Menten type function, yielding a Km of amiodarone of 2.45 mumol/l and a maximal desethylamiodarone concentration of 3.61 mumol/l.","Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4092724/),[μM] / [l],3.61,38463,DB01118,Amiodarone
,20472816,bioavailability,"It has an approximately 15% bioavailability, with plasma concentrations markedly increasing after a high-fat meal; it is recommended to be taken with food.",Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472816/),%,15,40252,DB01118,Amiodarone
,20472816,half-life,The primary metabolic clearance pathway for dronedarone is via the hepatic enzyme system (primarily cytochrome P450 3A4 [CYP3A4]); the half-life of dronedarone is 27 to 31 hours.,Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472816/),h,27 to 31,40253,DB01118,Amiodarone
,7174155,biologic half-life,The biologic half-life after p.o. administration (mean 17.1 h +/- S.D.) was higher than that calculated for the second phase after i.v. administration (mean 4.3 h +/- 0.98 S.D.).,Pharmacokinetics of amiodarone after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),h,17.1,43916,DB01118,Amiodarone
,7174155,biologic half-life,The biologic half-life after p.o. administration (mean 17.1 h +/- S.D.) was higher than that calculated for the second phase after i.v. administration (mean 4.3 h +/- 0.98 S.D.).,Pharmacokinetics of amiodarone after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),h,4.3,43917,DB01118,Amiodarone
,7174155,Total clearance rate,Total clearance rate during the second phase was within the range 125-288 ml/min after i.v. and 114-473 ml/min after p.o. administration.,Pharmacokinetics of amiodarone after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),[ml] / [min],125-288,43918,DB01118,Amiodarone
,7174155,Total clearance rate,Total clearance rate during the second phase was within the range 125-288 ml/min after i.v. and 114-473 ml/min after p.o. administration.,Pharmacokinetics of amiodarone after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),[ml] / [min],114-473,43919,DB01118,Amiodarone
,7174155,apparent volume of distribution in the central compartment,"The apparent volume of distribution in the central compartment after i.v. administration was found to be about 17.0 l and that calculated for the second elimination phase, 77 l, possibly indicating a concentration of the drug in the tissues.",Pharmacokinetics of amiodarone after intravenous and oral administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),l,17.0,43920,DB01118,Amiodarone
,7174155,apparent volume of distribution in the central compartment,"The apparent volume of distribution in the central compartment after i.v. administration was found to be about 17.0 l and that calculated for the second elimination phase, 77 l, possibly indicating a concentration of the drug in the tissues.",Pharmacokinetics of amiodarone after intravenous and oral administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),l,77,43921,DB01118,Amiodarone
,7174155,systemic availability,The systemic availability of amiodarone varied from 23 to 50% as determined on the basis of of the ratios of areas under p.o. and i.v. serum concentration curves for four subjects.,Pharmacokinetics of amiodarone after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174155/),%,23 to 50,43922,DB01118,Amiodarone
,6337802,peak serum concentration,Amiodarone is incompletely (approximately 50 percent) and slowly (peak serum concentration approximately 6 h) absorbed.,"Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),h,6,47537,DB01118,Amiodarone
,6337802,apparent elimination half-life,"It has an apparent elimination half-life of 15-45 days, which presents unique dosing problems.","Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),d,15-45,47538,DB01118,Amiodarone
,6337802,apparent therapeutic range,The apparent therapeutic range is 0.6-3 microgram/ml.,"Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6337802/),[μg] / [ml],0.6-3,47539,DB01118,Amiodarone
,27757923,solubilities,"The solubilities of AMD and its complex were 0.35 and 68.62 mg/mL, respectively, and the value of the inclusion complex was significantly improved by 196-fold compared with the solubility of free AMD.",Preparation and Characterization of the Sulfobutylether-β-Cyclodextrin Inclusion Complex of Amiodarone Hydrochloride with Enhanced Oral Bioavailability in Fasted State. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27757923/),[mg] / [ml],0.35,47601,DB01118,Amiodarone
,27757923,solubilities,"The solubilities of AMD and its complex were 0.35 and 68.62 mg/mL, respectively, and the value of the inclusion complex was significantly improved by 196-fold compared with the solubility of free AMD.",Preparation and Characterization of the Sulfobutylether-β-Cyclodextrin Inclusion Complex of Amiodarone Hydrochloride with Enhanced Oral Bioavailability in Fasted State. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27757923/),[mg] / [ml],68.62,47602,DB01118,Amiodarone
,10759694,AUC,"Grapefruit juice completely inhibited the production of N-DEA, the major metabolite of amiodarone, in all subjects and increased the area-under-the-curve (AUC) and maximum concentration of amiodarone (Cmax) by 50% and 84%, respectively, as compared with the control period during which water had been administrated instead of grapefruit juice (AUC: 35.9 +/- 14.3 vs 23.9 +/- 11.2 microg ml-1 h, P < 0.005 and Cmax: 3.45 +/- 1.7 vs 1.87 +/- 0.6 microg ml-1, P < 0. 02, respectively) (means +/- s.d.).",Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759694/),[h·μg] / [ml],35.9,50418,DB01118,Amiodarone
,10759694,AUC,"Grapefruit juice completely inhibited the production of N-DEA, the major metabolite of amiodarone, in all subjects and increased the area-under-the-curve (AUC) and maximum concentration of amiodarone (Cmax) by 50% and 84%, respectively, as compared with the control period during which water had been administrated instead of grapefruit juice (AUC: 35.9 +/- 14.3 vs 23.9 +/- 11.2 microg ml-1 h, P < 0.005 and Cmax: 3.45 +/- 1.7 vs 1.87 +/- 0.6 microg ml-1, P < 0. 02, respectively) (means +/- s.d.).",Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759694/),[h·μg] / [ml],23.9,50419,DB01118,Amiodarone
,10759694,Cmax,"Grapefruit juice completely inhibited the production of N-DEA, the major metabolite of amiodarone, in all subjects and increased the area-under-the-curve (AUC) and maximum concentration of amiodarone (Cmax) by 50% and 84%, respectively, as compared with the control period during which water had been administrated instead of grapefruit juice (AUC: 35.9 +/- 14.3 vs 23.9 +/- 11.2 microg ml-1 h, P < 0.005 and Cmax: 3.45 +/- 1.7 vs 1.87 +/- 0.6 microg ml-1, P < 0. 02, respectively) (means +/- s.d.).",Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759694/),[μg] / [ml],3.45,50420,DB01118,Amiodarone
,10759694,Cmax,"Grapefruit juice completely inhibited the production of N-DEA, the major metabolite of amiodarone, in all subjects and increased the area-under-the-curve (AUC) and maximum concentration of amiodarone (Cmax) by 50% and 84%, respectively, as compared with the control period during which water had been administrated instead of grapefruit juice (AUC: 35.9 +/- 14.3 vs 23.9 +/- 11.2 microg ml-1 h, P < 0.005 and Cmax: 3.45 +/- 1.7 vs 1.87 +/- 0.6 microg ml-1, P < 0. 02, respectively) (means +/- s.d.).",Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759694/),[μg] / [ml],1.87,50421,DB01118,Amiodarone
,31376827,oral bioavailability,"Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal.","Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376827/),%,4,51274,DB01118,Amiodarone
,31376827,oral bioavailability,"Dronedarone HCl (DRD), owing to its poor aqueous solubility and extensive presystemic metabolism shows low oral bioavailability of about 4% without food, which increases to approximately 15% when administered with a high fat meal.","Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376827/),%,15,51275,DB01118,Amiodarone
,31376827,entrapment efficiency,Optimized formulation of SLN showed particle size of 233 ± 42 nm and entrapment efficiency of 87.4 ± 1.29%.,"Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376827/),%,87.4,51276,DB01118,Amiodarone
,16415527,serum concentration to dose (C/D ratio),"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],47.8,56048,DB01118,Amiodarone
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],47.8,56049,DB01118,Amiodarone
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],95.3,56050,DB01118,Amiodarone
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],0.460,56051,DB01118,Amiodarone
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],0.879,56052,DB01118,Amiodarone
,16415527,concentration,"Furthermore, the mean S-carvedilol concentration over 14 days of coadministration with amiodarone was higher than that before coadministration (6.54+/-1.73 ng/mL versus 3.03+/-0.670 ng/mL, P<0.001).",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [ml],6.54,56053,DB01118,Amiodarone
,16415527,concentration,"Furthermore, the mean S-carvedilol concentration over 14 days of coadministration with amiodarone was higher than that before coadministration (6.54+/-1.73 ng/mL versus 3.03+/-0.670 ng/mL, P<0.001).",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [ml],3.03,56054,DB01118,Amiodarone
,25731867,solubility,AH exhibits poor aqueous solubility (0.3-0.5 mg/ml) and therefore variable oral bioavailability.,Development and Optimization of Solid Self Nanoemulsifying Drug Delivery (S-SNEDDS) Using D-Optimal Design for Improvement of Oral Bioavailability of Amiodarone Hydrochloride. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25731867/),[mg] / [ml],0.3-0.5,56319,DB01118,Amiodarone
,25731867,shelf life,The optimized S-SNEDDS was found to be stable and its shelf life was found to be 2.2 years.,Development and Optimization of Solid Self Nanoemulsifying Drug Delivery (S-SNEDDS) Using D-Optimal Design for Improvement of Oral Bioavailability of Amiodarone Hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25731867/),years,2.2,56320,DB01118,Amiodarone
,6175811,elimination half-life (t1/2beta),The drug disappeared from the blood with an elimination half-life (t1/2beta) of 514 min and distributed extensively into tissues [apparent volume of distribution (Vd)= 29.51 L/kg].,Pharmacokinetics of amiodarone in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175811/),min,514,61656,DB01118,Amiodarone
,6175811,apparent volume of distribution (Vd),The drug disappeared from the blood with an elimination half-life (t1/2beta) of 514 min and distributed extensively into tissues [apparent volume of distribution (Vd)= 29.51 L/kg].,Pharmacokinetics of amiodarone in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175811/),[l] / [kg],29.51,61657,DB01118,Amiodarone
,6175811,fat/blood concentration ratio,"Amiodarone accumulated extensively in adipose tissue and reached a fat/blood concentration ratio of about 1,000 at 16 h.",Pharmacokinetics of amiodarone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175811/),,"1,000",61658,DB01118,Amiodarone
,6175811,hepatic extraction ratio,Single-pass rat liver perfusion experiments gave an hepatic extraction ratio of 0.49 and an intrinsic clearance of 5.48 ml/min.,Pharmacokinetics of amiodarone in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175811/),,0.49,61659,DB01118,Amiodarone
,6175811,intrinsic clearance,Single-pass rat liver perfusion experiments gave an hepatic extraction ratio of 0.49 and an intrinsic clearance of 5.48 ml/min.,Pharmacokinetics of amiodarone in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175811/),[ml] / [min],5.48,61660,DB01118,Amiodarone
,6175811,half-life,"Amiodarone disappearance in rat liver recirculation experiments was biexponential, with a half-life of 58 min.",Pharmacokinetics of amiodarone in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175811/),min,58,61661,DB01118,Amiodarone
,6469441,peak serum digoxin levels (Cmax),This treatment caused a clear-cut rise in peak serum digoxin levels (Cmax) from 2.92 +/- 1.09 to 5.87 +/- 1.68 ng/ml (p less than 0.005) and a decrease of the peak time (Tmax) in four out of the six subjects.,Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469441/),[ng] / [ml],2.92,64490,DB01118,Amiodarone
,6469441,peak serum digoxin levels (Cmax),This treatment caused a clear-cut rise in peak serum digoxin levels (Cmax) from 2.92 +/- 1.09 to 5.87 +/- 1.68 ng/ml (p less than 0.005) and a decrease of the peak time (Tmax) in four out of the six subjects.,Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469441/),[ng] / [ml],5.87,64491,DB01118,Amiodarone
,6469441,area under the serum concentration-time curve (AUC),The area under the serum concentration-time curve (AUC) was increased by amiodarone with a high individual variability (30.71 +/- 6.15 vs 40.63 +/- 10.04 ng X h X ml-1).,Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469441/),[h·ng] / [ml],30.71,64492,DB01118,Amiodarone
,6469441,area under the serum concentration-time curve (AUC),The area under the serum concentration-time curve (AUC) was increased by amiodarone with a high individual variability (30.71 +/- 6.15 vs 40.63 +/- 10.04 ng X h X ml-1).,Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469441/),[h·ng] / [ml],40.63,64493,DB01118,Amiodarone
,6469441,recovery,"Also the 72-hour recovery of the glycoside in the urine was higher (258.77 +/- 68.41 vs 357.62 +/- 62.98 micrograms; p less than 0.01), while renal clearance (Clr) was not altered.",Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469441/),μg,258.77,64494,DB01118,Amiodarone
,6469441,recovery,"Also the 72-hour recovery of the glycoside in the urine was higher (258.77 +/- 68.41 vs 357.62 +/- 62.98 micrograms; p less than 0.01), while renal clearance (Clr) was not altered.",Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469441/),μg,357.62,64495,DB01118,Amiodarone
,26133712,absolute bioavailability,"The absolute bioavailability of the marketed product (Multaq, Sanofi, U.S.) was about 4% without food, but increased to 15% when administered with a high fat meal.",Reduced Food-Effect on Intestinal Absorption of Dronedarone by Self-microemulsifying Drug Delivery System (SMEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26133712/),%,4,72715,DB01118,Amiodarone
,26133712,absolute bioavailability,"The absolute bioavailability of the marketed product (Multaq, Sanofi, U.S.) was about 4% without food, but increased to 15% when administered with a high fat meal.",Reduced Food-Effect on Intestinal Absorption of Dronedarone by Self-microemulsifying Drug Delivery System (SMEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26133712/),%,15,72716,DB01118,Amiodarone
,9516032,plasma concentrations,"The mean cumulative amiodarone dose was 91 g and the mean plasma concentrations of amiodarone and desethylamiodarone were 0.68 and 0.84 microg.ml(-1), respectively.",Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516032/),[μg] / [ml],0.68,75543,DB01118,Amiodarone
,9516032,plasma concentrations,"The mean cumulative amiodarone dose was 91 g and the mean plasma concentrations of amiodarone and desethylamiodarone were 0.68 and 0.84 microg.ml(-1), respectively.",Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516032/),[μg] / [ml],0.84,75544,DB01118,Amiodarone
,9516032,tissue concentrations,The tissue concentrations of amiodarone amounted to 13.2 and 28.3 microg.,Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516032/),,13.2,75545,DB01118,Amiodarone
,9516032,tissue concentrations,The tissue concentrations of amiodarone amounted to 13.2 and 28.3 microg.,Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516032/),,28.3,75546,DB01118,Amiodarone
,9516032,g,g(-1) was reversed (3.3 compared with 0.29 in the ventricles).,Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516032/),,3.3,75547,DB01118,Amiodarone
,9516032,g,g(-1) was reversed (3.3 compared with 0.29 in the ventricles).,Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516032/),,0.29,75548,DB01118,Amiodarone
,6613830,terminal elimination half-life,"In patients the terminal elimination half-life was on the order of 40 days, with a more rapid phase of elimination in the first few days following the withdrawal of therapy.",Amiodarone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613830/),d,40,76365,DB01118,Amiodarone
,3967454,maximum plasma level,"After oral dosing, amiodarone was slowly absorbed and the maximum plasma level (0.55 +/- 0.20 mg/l) was reached in 4.5 hr.",Absolute bioavailability of amiodarone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967454/),[mg] / [l],0.55,77241,DB01118,Amiodarone
,3967454,oral bioavailability,A mean oral bioavailability of 65% +/- 22% was indicated.,Absolute bioavailability of amiodarone in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967454/),%,65,77242,DB01118,Amiodarone
,18161885,hepatic extraction ratio,"The hepatic extraction ratio of DEA was 0.48, similar to that of AM (0.51).","Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18161885/),,0.48,79349,DB01118,Amiodarone
,18161885,hepatic extraction ratio,"The hepatic extraction ratio of DEA was 0.48, similar to that of AM (0.51).","Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18161885/),,0.51,79350,DB01118,Amiodarone
,18161885,oral bioavailability,Oral AM demonstrated higher plasma AUC (5.6 fold) and higher C(max) (6.1 fold) than oral DEA and oral bioavailability of AM (46%) was greater than DEA (17%).,"Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18161885/),%,46,79351,DB01118,Amiodarone
,18161885,oral bioavailability,Oral AM demonstrated higher plasma AUC (5.6 fold) and higher C(max) (6.1 fold) than oral DEA and oral bioavailability of AM (46%) was greater than DEA (17%).,"Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18161885/),%,17,79352,DB01118,Amiodarone
,6736437,elimination half-life,"Amiodarone caused a 31% prolongation of digoxin elimination half-life from 49.5 +/- 8.8 to 65.0 +/- 28.8 hours, but the increase in half-life was not statistically significant.","Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736437/),h,49.5,79413,DB01118,Amiodarone
,6736437,elimination half-life,"Amiodarone caused a 31% prolongation of digoxin elimination half-life from 49.5 +/- 8.8 to 65.0 +/- 28.8 hours, but the increase in half-life was not statistically significant.","Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736437/),h,65.0,79414,DB01118,Amiodarone
,6736437,Total body clearance,"Total body clearance was reduced significantly (29%, p less than 0.05) from 2.05 +/- 0.76 to 1.46 +/- 0.64 ml/min per kg.","Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736437/),[ml] / [kg·min],2.05,79415,DB01118,Amiodarone
,6736437,Total body clearance,"Total body clearance was reduced significantly (29%, p less than 0.05) from 2.05 +/- 0.76 to 1.46 +/- 0.64 ml/min per kg.","Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736437/),[ml] / [kg·min],1.46,79416,DB01118,Amiodarone
,6736437,Nonrenal clearance,"Nonrenal clearance also showed a significant decrease (33%, p less than 0.05) from 1.20 +/- 0.46 to 0.80 +/- 0.30 ml/min per kg.","Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736437/),[ml] / [kg·min],1.20,79417,DB01118,Amiodarone
,6736437,Nonrenal clearance,"Nonrenal clearance also showed a significant decrease (33%, p less than 0.05) from 1.20 +/- 0.46 to 0.80 +/- 0.30 ml/min per kg.","Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6736437/),[ml] / [kg·min],0.80,79418,DB01118,Amiodarone
,10439890,myocardial/plasma amiodarone ratio,"At 2.5 +/- 1.2 minutes after amiodarone administration, the mean myocardial concentration was 95.7 +/- 67.4 micrograms/g (range, 16-175), and the myocardial/plasma amiodarone ratio was 5.05 +/- 5.01.",Amiodarone concentration in human myocardium after rapid intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10439890/),,5.05,82744,DB01118,Amiodarone
,10439890,Heart rate,"Heart rate increased from 82 +/- 17 to 90 +/- 13 beats/min (P < 0.05), and systolic blood pressure decreased from 132 +/- 19 to 118 +/- 17 mmHg (P < 0.03).",Amiodarone concentration in human myocardium after rapid intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10439890/),[beats] / [min],82,82745,DB01118,Amiodarone
,10439890,Heart rate,"Heart rate increased from 82 +/- 17 to 90 +/- 13 beats/min (P < 0.05), and systolic blood pressure decreased from 132 +/- 19 to 118 +/- 17 mmHg (P < 0.03).",Amiodarone concentration in human myocardium after rapid intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10439890/),[beats] / [min],90,82746,DB01118,Amiodarone
,3919673,half-life,The half-life of the first exponential is 4.9 hours ; the half-life of the second one is 544 hours.,[Acute amiodarone poisoning. Clinical and pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919673/),h,4.9,84476,DB01118,Amiodarone
,3919673,half-life,The half-life of the first exponential is 4.9 hours ; the half-life of the second one is 544 hours.,[Acute amiodarone poisoning. Clinical and pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919673/),h,544,84477,DB01118,Amiodarone
,2273084,ASC,"Observed ASC during weeks 5 and 6 were (mean +/- SD) 0.25 +/- 0.09 micrograms/mL and 0.19 +/- 0.07 micrograms/mL, respectively.",Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.25,84977,DB01118,Amiodarone
,2273084,ASC,"Observed ASC during weeks 5 and 6 were (mean +/- SD) 0.25 +/- 0.09 micrograms/mL and 0.19 +/- 0.07 micrograms/mL, respectively.",Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.19,84978,DB01118,Amiodarone
,2273084,ASC,Corresponding predicted ASC were 0.36 +/- 0.12 micrograms/mL (P = .011) and 0.38 +/- 0.13 micrograms/mL (P = .004).,Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.36,84979,DB01118,Amiodarone
,2273084,ASC,Corresponding predicted ASC were 0.36 +/- 0.12 micrograms/mL (P = .011) and 0.38 +/- 0.13 micrograms/mL (P = .004).,Effect of phenytoin on the clinical pharmacokinetics of amiodarone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273084/),[μg] / [ml],0.38,84980,DB01118,Amiodarone
,2444790,t1/2 alpha,"The first pattern is biexponential decline in plasma drug levels with a rapid distribution phase (t1/2 alpha = 5.1 +/- 2.1 min for AM and 5.5 +/- 1.2 min for DA, respectively) and a slower elimination phase (t1/2 beta = 3.7 +/- 1.3 h for AM and 4.96 +/- 0.8 h for DA, respectively).","A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2444790/),min,5.1,86420,DB01118,Amiodarone
,2444790,t1/2 alpha,"The first pattern is biexponential decline in plasma drug levels with a rapid distribution phase (t1/2 alpha = 5.1 +/- 2.1 min for AM and 5.5 +/- 1.2 min for DA, respectively) and a slower elimination phase (t1/2 beta = 3.7 +/- 1.3 h for AM and 4.96 +/- 0.8 h for DA, respectively).","A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2444790/),min,5.5,86421,DB01118,Amiodarone
,2444790,t1/2 beta,"The first pattern is biexponential decline in plasma drug levels with a rapid distribution phase (t1/2 alpha = 5.1 +/- 2.1 min for AM and 5.5 +/- 1.2 min for DA, respectively) and a slower elimination phase (t1/2 beta = 3.7 +/- 1.3 h for AM and 4.96 +/- 0.8 h for DA, respectively).","A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2444790/),h,3.7,86422,DB01118,Amiodarone
,2444790,t1/2 beta,"The first pattern is biexponential decline in plasma drug levels with a rapid distribution phase (t1/2 alpha = 5.1 +/- 2.1 min for AM and 5.5 +/- 1.2 min for DA, respectively) and a slower elimination phase (t1/2 beta = 3.7 +/- 1.3 h for AM and 4.96 +/- 0.8 h for DA, respectively).","A comparison of plasma, white blood cell, red blood cell, and tissue distribution of amiodarone and desethylamiodarone in anesthetized dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2444790/),h,4.96,86423,DB01118,Amiodarone
,3396616,Terminal half-life (t1/2 el),Terminal half-life (t1/2 el) of amiodarone increased from a mean (SD) 24.1 +/- 19.5 h after the first dose to 20.4 +/- 4.8 days after the last dose.,Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396616/),h,24.1,93582,DB01118,Amiodarone
,3396616,Terminal half-life (t1/2 el),Terminal half-life (t1/2 el) of amiodarone increased from a mean (SD) 24.1 +/- 19.5 h after the first dose to 20.4 +/- 4.8 days after the last dose.,Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396616/),d,20.4,93583,DB01118,Amiodarone
,3396616,apparent t el,Desethylamiodarone slowly appeared in the plasma after the first oral dose and its apparent t el was 61.6 +/- 26.6 h.,Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396616/),h,61.6,93584,DB01118,Amiodarone
,3396616,apparent t1/2 el,After one-month dosing apparent t1/2 el of desethylamiodarone increased to 29.5 +/- 9.7 days.,Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396616/),d,29.5,93585,DB01118,Amiodarone
,3396616,maximal plasma amiodarone/desethylamiodarone concentration ratio,Mean maximal plasma amiodarone/desethylamiodarone concentration ratio decreased from 9.2 +/- 5.0 to 2.0 +/- 0.6 after chronic dosing.,Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396616/),,9.2,93586,DB01118,Amiodarone
,3396616,maximal plasma amiodarone/desethylamiodarone concentration ratio,Mean maximal plasma amiodarone/desethylamiodarone concentration ratio decreased from 9.2 +/- 5.0 to 2.0 +/- 0.6 after chronic dosing.,Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396616/),,2.0,93587,DB01118,Amiodarone
,14962511,half-life for total elimination,The half-life for total elimination was calculated to be 16.3 days with 99% eliminated by 97 days.,Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962511/),d,16.3,94938,DB01118,Amiodarone
,16506906,terminal elimination half-lives,"After IV administration, median terminal elimination half-lives of amiodarone and desethylamiodarone were 51.1 and 75.3 hours, respectively.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),h,51.1,97453,DB01118,Amiodarone
,16506906,terminal elimination half-lives,"After IV administration, median terminal elimination half-lives of amiodarone and desethylamiodarone were 51.1 and 75.3 hours, respectively.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),h,75.3,97454,DB01118,Amiodarone
,16506906,Clearance,"Clearance was 0.35 L/kg x h, and the apparent volume of distribution for amiodarone was 31.1 L/kg.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),[l] / [h·kg],0.35,97455,DB01118,Amiodarone
,16506906,apparent volume of distribution,"Clearance was 0.35 L/kg x h, and the apparent volume of distribution for amiodarone was 31.1 L/kg.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),[l] / [kg],31.1,97456,DB01118,Amiodarone
,16506906,peak plasma desethylamiodarone concentration,The peak plasma desethylamiodarone concentration of 0.08 microg/mL was attained 2.7 hours after IV administration.,Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),[μg] / [ml],0.08,97457,DB01118,Amiodarone
,16506906,protein binding,"Neither parent drug nor metabolite was detected in urine, and protein binding of amiodarone was 96%.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),%,96,97458,DB01118,Amiodarone
,16506906,bioavailability,"After oral administration of amiodarone, absorption of amiodarone was slow and variable; bioavailability ranged from 6.0% to 33.7%.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),%,6.0,97459,DB01118,Amiodarone
,16506906,bioavailability,"After oral administration of amiodarone, absorption of amiodarone was slow and variable; bioavailability ranged from 6.0% to 33.7%.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),%,33.7,97460,DB01118,Amiodarone
,16506906,peak plasma amiodarone concentration,The peak plasma amiodarone concentration of 0.14 microg/mL was attained 7.0 hours after oral administration and the peak plasma desethylamiodarone concentration of 0.03 microg/mL was attained 8.0 hours after administration.,Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),[μg] / [ml],0.14,97461,DB01118,Amiodarone
,16506906,peak plasma desethylamiodarone concentration,The peak plasma amiodarone concentration of 0.14 microg/mL was attained 7.0 hours after oral administration and the peak plasma desethylamiodarone concentration of 0.03 microg/mL was attained 8.0 hours after administration.,Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),[μg] / [ml],0.03,97462,DB01118,Amiodarone
,16506906,elimination half-lives,"Median elimination half-lives of amiodarone and desethylamiodarone were 24.1 and 58.6 hours, respectively.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),h,24.1,97463,DB01118,Amiodarone
,16506906,elimination half-lives,"Median elimination half-lives of amiodarone and desethylamiodarone were 24.1 and 58.6 hours, respectively.",Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506906/),h,58.6,97464,DB01118,Amiodarone
,20733043,C(min),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],3.80,100293,DB01118,Amiodarone
,20733043,C(max),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],14.70,100294,DB01118,Amiodarone
,20733043,AUC(24),"A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C(min), 14.70 mg/liter [10.57 to 19.64] for C(max), and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC(24)).",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[h·mg] / [l],196.08,100295,DB01118,Amiodarone
≥,20733043,C(min),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],2,100296,DB01118,Amiodarone
>,20733043,AUC(24)/MIC(90) ratio,"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),,80,100297,DB01118,Amiodarone
≥,20733043,C(min),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[mg] / [l],10,100298,DB01118,Amiodarone
≥,20733043,AUC(24),"Optimal pharmacodynamic target attainment (defined as C(min) of ≥2 mg/liter and/or AUC(24)/MIC(90) ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C(min) of ≥10 mg/liter and/or AUC(24) of ≥400 mg·h/liter) was documented in about 12% of cases.",Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20733043/),[h·mg] / [l],400,100299,DB01118,Amiodarone
,8792951,steady-state volume of distribution,"Amiodarone pharmacokinetics demonstrate extensive interpatient variability and are characterized by wide tissue distribution (steady-state volume of distribution 40-84 L/kg), slow total body clearance (90-158 mL/h/kg), long terminal elimination half-life (20-47 d), and extensive hepatic metabolism.","Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792951/),[l] / [kg],40-84,102944,DB01118,Amiodarone
,8792951,total body clearance,"Amiodarone pharmacokinetics demonstrate extensive interpatient variability and are characterized by wide tissue distribution (steady-state volume of distribution 40-84 L/kg), slow total body clearance (90-158 mL/h/kg), long terminal elimination half-life (20-47 d), and extensive hepatic metabolism.","Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792951/),[ml] / [h·kg],90-158,102945,DB01118,Amiodarone
,8792951,terminal elimination half-life,"Amiodarone pharmacokinetics demonstrate extensive interpatient variability and are characterized by wide tissue distribution (steady-state volume of distribution 40-84 L/kg), slow total body clearance (90-158 mL/h/kg), long terminal elimination half-life (20-47 d), and extensive hepatic metabolism.","Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792951/),d,20-47,102946,DB01118,Amiodarone
,4007030,clearance,"Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p less than 0.01) with similar plasma concentrations (1.5 vs 1.2 micrograms/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively).",Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007030/),[ml] / [min],1.4,103237,DB01118,Amiodarone
,4007030,clearance,"Warfarin clearance was lower in amiodarone-treated patients than in the controls (1.4 vs 3.1 ml/min, p less than 0.01) with similar plasma concentrations (1.5 vs 1.2 micrograms/ml) despite administration of lower doses (23.3 vs 39 mg/week respectively).",Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007030/),[ml] / [min],3.1,103238,DB01118,Amiodarone
,21052689,C (max),"The maximum plasma concentration (C (max)) and area under the concentration-time curve (AUC(0-96)) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C (max) was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC(0-96) was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively.",Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),[ng] / [ml],"2,920",110434,DB01118,Amiodarone
,21052689,C (max),"The maximum plasma concentration (C (max)) and area under the concentration-time curve (AUC(0-96)) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C (max) was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC(0-96) was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively.",Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),[ng] / [ml],"7,140",110435,DB01118,Amiodarone
,21052689,C (max),"The maximum plasma concentration (C (max)) and area under the concentration-time curve (AUC(0-96)) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C (max) was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC(0-96) was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively.",Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),[ng] / [ml],"13,660",110436,DB01118,Amiodarone
,21052689,AUC(0-96),"The maximum plasma concentration (C (max)) and area under the concentration-time curve (AUC(0-96)) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C (max) was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC(0-96) was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively.",Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),[h·ng] / [ml],"3,600",110437,DB01118,Amiodarone
,21052689,AUC(0-96),"The maximum plasma concentration (C (max)) and area under the concentration-time curve (AUC(0-96)) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C (max) was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC(0-96) was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively.",Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),[h·ng] / [ml],"8,100",110438,DB01118,Amiodarone
,21052689,AUC(0-96),"The maximum plasma concentration (C (max)) and area under the concentration-time curve (AUC(0-96)) for amiodarone 1.25, 2.5 and 5.0 mg/kg displayed dose-dependent characteristics: mean C (max) was 2,920 ± 610, 7,140 ± 1,480 and 13,660 ± 3,410 ng/ml, respectively; the mean AUC(0-96) was 3,600 ± 700, 8,100 ± 1,600 and 16,600 ± 4,300 ng h/ml, respectively.",Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),[h·ng] / [ml],"16,600",110439,DB01118,Amiodarone
>,21052689,serum half-life,A long serum half-life (>14 days) was observed for amiodarone and desethylamiodarone.,Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21052689/),d,14,110440,DB01118,Amiodarone
,22977121,flow rate,"The mobile phase, consisting of phosphate buffer (50 mM) with 0.1% formic acid (pH 3.1)-methanol-acetonitrile (45:5:50, v/v/v), was pumped isocratically at a flow rate of 1.2 mL/min.",A rapid HPLC method for the simultaneous determination of amiodarone and its major metabolite in rat plasma and tissues: a useful tool for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22977121/),[ml] / [min],1.2,117760,DB01118,Amiodarone
,22977121,recovery,Amiodarone and desethylamiodarone were extracted from rat matrices by a liquid-liquid extraction procedure and the mean recovery ranged from 59.9 to 97.6%.,A rapid HPLC method for the simultaneous determination of amiodarone and its major metabolite in rat plasma and tissues: a useful tool for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22977121/),%,59.9 to 97.6,117761,DB01118,Amiodarone
,27313453,zeta potential,"The optimum formulation was quantitatively obtained with a diameter of 99.9±0.4 nm, a zeta potential of 35.1±10.9 mV, and an encapsulation efficiency of 99.5%±13.3%.",Preparation of liposomal amiodarone and investigation of its cardiomyocyte-targeting ability in cardiac radiofrequency ablation rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27313453/),mv,35.1,119494,DB01118,Amiodarone
,3129880,concentrations,"Just prior to the first morning dose, amiodarone concentrations in plasma were 1.0-2.9 (2.0 +/- 0.6) micrograms/ml, in saliva 0.02-0.25 micrograms/ml; flecainide in plasma 80-560 (316 +/- 163) ng/ml, in saliva 630-3700 (1749 +/- 963) ng/ml.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],316,121796,DB01118,Amiodarone
,3129880,concentrations,"Just prior to the first morning dose, amiodarone concentrations in plasma were 1.0-2.9 (2.0 +/- 0.6) micrograms/ml, in saliva 0.02-0.25 micrograms/ml; flecainide in plasma 80-560 (316 +/- 163) ng/ml, in saliva 630-3700 (1749 +/- 963) ng/ml.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],1749,121797,DB01118,Amiodarone
,3129880,maximal flecainide,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],462,121798,DB01118,Amiodarone
,3129880,plasma levels,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],462,121799,DB01118,Amiodarone
,3129880,plasma levels,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],3218,121800,DB01118,Amiodarone
,3129880,saliva,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],3218,121801,DB01118,Amiodarone
,3129880,concentrations,"The highest flecainide concentrations in the saliva (13,400 and 11,300 ng/ml) were found in two patients 30 and 60 min after the morning dose.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],"13,400",121802,DB01118,Amiodarone
,3129880,concentrations,"The highest flecainide concentrations in the saliva (13,400 and 11,300 ng/ml) were found in two patients 30 and 60 min after the morning dose.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],"11,300",121803,DB01118,Amiodarone
,2337037,area under the serum concentration time curve,"During amiodarone therapy, area under the serum concentration time curve for phenytoin was increased from 208 +/- 82.8 (mean +/- standard deviation) to 292 +/- 108 mg.hr/liter (p = 0.015).",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[h·mg] / [l],208,125630,DB01118,Amiodarone
,2337037,area under the serum concentration time curve,"During amiodarone therapy, area under the serum concentration time curve for phenytoin was increased from 208 +/- 82.8 (mean +/- standard deviation) to 292 +/- 108 mg.hr/liter (p = 0.015).",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[h·mg] / [l],292,125631,DB01118,Amiodarone
,2337037,maximum,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.75,125632,DB01118,Amiodarone
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.75,125633,DB01118,Amiodarone
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],6.67,125634,DB01118,Amiodarone
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],14.26,125635,DB01118,Amiodarone
,2337037,24-hour,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.27,125636,DB01118,Amiodarone
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.75,125637,DB01118,Amiodarone
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],6.67,125638,DB01118,Amiodarone
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],14.26,125639,DB01118,Amiodarone
,2337037,p,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.27,125640,DB01118,Amiodarone
,2337037,concentrations,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],6.67,125641,DB01118,Amiodarone
,2337037,concentrations,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],14.26,125642,DB01118,Amiodarone
,2337037,concentrations,"Both the maximum and 24-hour phenytoin concentrations were increased from 10.75 +/- 3.75 and 6.67 +/- 3.51 micrograms/ml to 14.26 +/- 3.97 (p = 0.016) and 10.27 +/- 4.67 micrograms/ml (p = 0.012), respectively, during concomitant amiodarone treatment.",Steady-state interaction between amiodarone and phenytoin in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[μg] / [ml],10.27,125643,DB01118,Amiodarone
,2337037,oral clearance,Amiodarone caused a decrease in the oral clearance of phenytoin from 1.29 +/- 0.30 to 0.93 +/- 0.25 liters/hr (p = 0.002).,Steady-state interaction between amiodarone and phenytoin in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[l] / [h],1.29,125644,DB01118,Amiodarone
,2337037,oral clearance,Amiodarone caused a decrease in the oral clearance of phenytoin from 1.29 +/- 0.30 to 0.93 +/- 0.25 liters/hr (p = 0.002).,Steady-state interaction between amiodarone and phenytoin in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337037/),[l] / [h],0.93,125645,DB01118,Amiodarone
,3418508,terminal disposition half-life (T1/2 gamma),"Accompanying the decreases in CL were increases in the terminal disposition half-life (T1/2 gamma), 89% (18-34 hr) with the 45-mg/kg dose and 185% (20-57 hr) after the 80-mg/kg dose.",Amiodarone pharmacokinetics. Influence of thyroid dysfunction on amiodarone absorption and disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418508/),h,18-34,126593,DB01118,Amiodarone
,3418508,CL,"In the hyperthyroid rats, a 67% increase in CL (12.8-21.4 ml/min/kg) and 75 to 80% increases in Vss (15.5-27.1 liters/kg) and Vd (25.0-44.8 liters/kg) were observed with the 45-mg/kg of amiodarone dose.",Amiodarone pharmacokinetics. Influence of thyroid dysfunction on amiodarone absorption and disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418508/),[ml] / [kg·min],12.8-21.4,126594,DB01118,Amiodarone
,3418508,Vss,"In the hyperthyroid rats, a 67% increase in CL (12.8-21.4 ml/min/kg) and 75 to 80% increases in Vss (15.5-27.1 liters/kg) and Vd (25.0-44.8 liters/kg) were observed with the 45-mg/kg of amiodarone dose.",Amiodarone pharmacokinetics. Influence of thyroid dysfunction on amiodarone absorption and disposition. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418508/),[l] / [kg],15.5-27.1,126595,DB01118,Amiodarone
,3418508,Vd,"In the hyperthyroid rats, a 67% increase in CL (12.8-21.4 ml/min/kg) and 75 to 80% increases in Vss (15.5-27.1 liters/kg) and Vd (25.0-44.8 liters/kg) were observed with the 45-mg/kg of amiodarone dose.",Amiodarone pharmacokinetics. Influence of thyroid dysfunction on amiodarone absorption and disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418508/),[l] / [kg],25.0-44.8,126596,DB01118,Amiodarone
,6370540,oral bioavailability,Available evidence suggests that absorption of amiodarone following oral administration is erratic and unpredictable; oral bioavailability ranges from 22 to 86%.,Clinical pharmacokinetics of amiodarone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,22 to 86,128509,DB01118,Amiodarone
,6370540,protein binding,In vitro protein binding of amiodarone has been reported to be 96.3 +/- 0.6%.,Clinical pharmacokinetics of amiodarone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,96.3,128510,DB01118,Amiodarone
,6370540,plasma half-life,The plasma half-life of amiodarone after single-dose administration has been reported to be in the range of 3.2 to 79.7 hours.,Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,3.2 to 79.7,128511,DB01118,Amiodarone
,6370540,half-life,"However, after withdrawal of long term amiodarone treatment the half-life is as long as 100 days.",Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),d,100,128512,DB01118,Amiodarone
,6370540,Total body clearance,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [min],0.10 to 0.77,128513,DB01118,Amiodarone
,6370540,apparent volume of distribution,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [kg],0.9 and 148,128514,DB01118,Amiodarone
,6370540,time of onset of action,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),min,1 and 30,128515,DB01118,Amiodarone
,6370540,duration of effect,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,1 and 3,128516,DB01118,Amiodarone
,3944239,excretion,Urinary inorganic iodide excretion increased from 0.25 +/- 0.03 (+/- SE) mumol/mmol creatinine before treatment to over 7 mumol/mmol during therapy.,Iodine kinetic studies during amiodarone treatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[μM] / [mM],0.25,130737,DB01118,Amiodarone
over,3944239,excretion,Urinary inorganic iodide excretion increased from 0.25 +/- 0.03 (+/- SE) mumol/mmol creatinine before treatment to over 7 mumol/mmol during therapy.,Iodine kinetic studies during amiodarone treatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),μM,7,130738,DB01118,Amiodarone
,3944239,clearance,"Thyroid iodide clearance fell from 5.93 +/- 0.82 ml/min to less than 0.5 ml/min, while plasma inorganic iodide rose from 0.05 +/- 0.01 mumol/liter to approximately 2.2 mumol/liter during treatment.",Iodine kinetic studies during amiodarone treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[ml] / [min],5.93,130739,DB01118,Amiodarone
less,3944239,clearance,"Thyroid iodide clearance fell from 5.93 +/- 0.82 ml/min to less than 0.5 ml/min, while plasma inorganic iodide rose from 0.05 +/- 0.01 mumol/liter to approximately 2.2 mumol/liter during treatment.",Iodine kinetic studies during amiodarone treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[ml] / [min],0.5,130740,DB01118,Amiodarone
,3944239,clearance,"Thyroid iodide clearance fell from 5.93 +/- 0.82 ml/min to less than 0.5 ml/min, while plasma inorganic iodide rose from 0.05 +/- 0.01 mumol/liter to approximately 2.2 mumol/liter during treatment.",Iodine kinetic studies during amiodarone treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[μM] / [l],0.05,130741,DB01118,Amiodarone
,3944239,clearance,"Thyroid iodide clearance fell from 5.93 +/- 0.82 ml/min to less than 0.5 ml/min, while plasma inorganic iodide rose from 0.05 +/- 0.01 mumol/liter to approximately 2.2 mumol/liter during treatment.",Iodine kinetic studies during amiodarone treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[μM] / [l],2.2,130742,DB01118,Amiodarone
,3944239,absolute iodide,Thyroid absolute iodide uptake rose from 16.3 +/- 2.7 to 54.6 +/- 5.7 nmol/h after 6 weeks of therapy (P less than 0.001).,Iodine kinetic studies during amiodarone treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[nM] / [h],16.3,130743,DB01118,Amiodarone
,3944239,absolute iodide,Thyroid absolute iodide uptake rose from 16.3 +/- 2.7 to 54.6 +/- 5.7 nmol/h after 6 weeks of therapy (P less than 0.001).,Iodine kinetic studies during amiodarone treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[nM] / [h],54.6,130744,DB01118,Amiodarone
,3944239,uptake,Thyroid absolute iodide uptake rose from 16.3 +/- 2.7 to 54.6 +/- 5.7 nmol/h after 6 weeks of therapy (P less than 0.001).,Iodine kinetic studies during amiodarone treatment. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[nM] / [h],16.3,130745,DB01118,Amiodarone
,3944239,uptake,Thyroid absolute iodide uptake rose from 16.3 +/- 2.7 to 54.6 +/- 5.7 nmol/h after 6 weeks of therapy (P less than 0.001).,Iodine kinetic studies during amiodarone treatment. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),[nM] / [h],54.6,130746,DB01118,Amiodarone
over,3944239,daily excretion,"The calculated daily excretion of inorganic iodide rose to over 80 mumol during the study, accounting for about 10% of amiodarone iodine.",Iodine kinetic studies during amiodarone treatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3944239/),μM,80,130747,DB01118,Amiodarone
,3327698,half-lives,The half-lives of the first two phases were 3.2 to 11.4 h for t1/2 alpha 1 and 22.7 to 50.3 h for t1/2 alpha 2 in plasma.,Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327698/),h,3.2 to 11.4,130827,DB01118,Amiodarone
,3327698,t1/2 alpha 1,The half-lives of the first two phases were 3.2 to 11.4 h for t1/2 alpha 1 and 22.7 to 50.3 h for t1/2 alpha 2 in plasma.,Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327698/),h,3.2 to 11.4,130828,DB01118,Amiodarone
,3327698,t1/2 alpha 2,The half-lives of the first two phases were 3.2 to 11.4 h for t1/2 alpha 1 and 22.7 to 50.3 h for t1/2 alpha 2 in plasma.,Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327698/),h,22.7 to 50.3,130829,DB01118,Amiodarone
,3327698,half-life of the terminal phase (t1/2 beta),The half-life of the terminal phase (t1/2 beta) was between 9 and 18.2 days.,Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327698/),d,9 and 18.2,130830,DB01118,Amiodarone
,2979794,absorption half-life,The mean absorption half-life of amiodarone was 1.83 h for both dosages and the mean elimination half-life was 15 h after the 100 mg/kg dosage and 105 h after the 200 mg/kg dosage.,Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979794/),h,1.83,132110,DB01118,Amiodarone
,2979794,elimination half-life,The mean absorption half-life of amiodarone was 1.83 h for both dosages and the mean elimination half-life was 15 h after the 100 mg/kg dosage and 105 h after the 200 mg/kg dosage.,Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979794/),h,15,132111,DB01118,Amiodarone
,2979794,elimination half-life,The mean absorption half-life of amiodarone was 1.83 h for both dosages and the mean elimination half-life was 15 h after the 100 mg/kg dosage and 105 h after the 200 mg/kg dosage.,Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979794/),h,105,132112,DB01118,Amiodarone
,2979794,bioavailability,The mean bioavailability of oral amiodarone ranged from 17% to 60% with an average of 39%.,Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979794/),%,17,132113,DB01118,Amiodarone
,2979794,bioavailability,The mean bioavailability of oral amiodarone ranged from 17% to 60% with an average of 39%.,Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979794/),%,60,132114,DB01118,Amiodarone
,2979794,bioavailability,The mean bioavailability of oral amiodarone ranged from 17% to 60% with an average of 39%.,Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979794/),%,39,132115,DB01118,Amiodarone
,8472722,half-life,A peak concentration is reached 1.5 h after drug intake; elimination from the plasma compartment has a half-life of 1.5 h.,"Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472722/),h,1.5,132125,DB01118,Amiodarone
,19875005,bioavailability,"The main pharmacokinetic characteristics of dabigatran are a bioavailability of approximately 7.5%, a maximum concentration obtained in 0.5 to 2 hours, a terminal half-life of elimination of 7 to 17 hours, a renal way of elimination, 80% as unchanged form and 20% as glucuronide conjugate.",[Dabigatran: clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875005/),%,7.5,140899,DB01118,Amiodarone
,19875005,terminal half-life of elimination,"The main pharmacokinetic characteristics of dabigatran are a bioavailability of approximately 7.5%, a maximum concentration obtained in 0.5 to 2 hours, a terminal half-life of elimination of 7 to 17 hours, a renal way of elimination, 80% as unchanged form and 20% as glucuronide conjugate.",[Dabigatran: clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875005/),h,7 to 17,140900,DB01118,Amiodarone
,23338943,elimination half-life,"Multiple studies have shown that amiodarone is effective in treating atrial fibrillation (AF), but is associated with a relatively high incidence of side effects; however, due to amiodarone's long elimination half-life (20-100 days), physicians may hesitate to start other drugs until it has fully cleared.",Effects of dronedarone started rapidly after amiodarone discontinuation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23338943/),d,20-100,142796,DB01118,Amiodarone
,18548509,steady-state plasma concentration,The mean steady-state plasma concentration of 1.7+/-0.1 micromol/l was reached and the total clearance achieved 17.7+/-1.0 ml/min/kg.,Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18548509/),[μM] / [l],1.7,147060,DB01118,Amiodarone
,18548509,total clearance,The mean steady-state plasma concentration of 1.7+/-0.1 micromol/l was reached and the total clearance achieved 17.7+/-1.0 ml/min/kg.,Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18548509/),[ml] / [kg·min],17.7,147061,DB01118,Amiodarone
,28034694,clearance,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,39,151866,DB01118,Amiodarone
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,60,151867,DB01118,Amiodarone
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,46,151868,DB01118,Amiodarone
,28034694,bioavailability,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,38,151869,DB01118,Amiodarone
,2632911,maximal concentrations,Mean values of individual maximal concentrations and time for reaching them did not significantly differ and were respectively 0.828 +/- 0.401 microgram/ml and 4.4 +/- 1.5 h for Amiodarone preparation Polfa and 0.541 +/- 0.207 microgram/ml and 5.2 +/- 1.6 h for Cordarone preparation.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),[μg] / [ml],0.828,153690,DB01118,Amiodarone
,2632911,maximal concentrations,Mean values of individual maximal concentrations and time for reaching them did not significantly differ and were respectively 0.828 +/- 0.401 microgram/ml and 4.4 +/- 1.5 h for Amiodarone preparation Polfa and 0.541 +/- 0.207 microgram/ml and 5.2 +/- 1.6 h for Cordarone preparation.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),[μg] / [ml],0.541,153691,DB01118,Amiodarone
,2632911,time for reaching them,Mean values of individual maximal concentrations and time for reaching them did not significantly differ and were respectively 0.828 +/- 0.401 microgram/ml and 4.4 +/- 1.5 h for Amiodarone preparation Polfa and 0.541 +/- 0.207 microgram/ml and 5.2 +/- 1.6 h for Cordarone preparation.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),h,4.4,153692,DB01118,Amiodarone
,2632911,time for reaching them,Mean values of individual maximal concentrations and time for reaching them did not significantly differ and were respectively 0.828 +/- 0.401 microgram/ml and 4.4 +/- 1.5 h for Amiodarone preparation Polfa and 0.541 +/- 0.207 microgram/ml and 5.2 +/- 1.6 h for Cordarone preparation.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),h,5.2,153693,DB01118,Amiodarone
,2632911,Bioavailability extent (EBA),Bioavailability extent (EBA) of examined preparation was 120 per cent in comparison with the standard one.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),%,120,153694,DB01118,Amiodarone
,2632911,Absorption rate constant Ka,Absorption rate constant Ka did not statistically significant differ and was respectively 0.35 +/- 0.10 1/h and 0.49 +/- 0.35 1/h.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),[1] / [h],0.35,153695,DB01118,Amiodarone
,2632911,Absorption rate constant Ka,Absorption rate constant Ka did not statistically significant differ and was respectively 0.35 +/- 0.10 1/h and 0.49 +/- 0.35 1/h.,[Evaluation of the relative biological availability of amiodarone Polfa preparation after extravascular administration of a single dose]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2632911/),[1] / [h],0.49,153696,DB01118,Amiodarone
,22985658,AFT,"Before drug administration, LCx coronary artery stenosis lowered AFT from 25.2 ± 1.7 mA control (mean ± SEM) to 4.9 ± 1.0 mA baseline (P<.01).",Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22985658/),m,25.2,155719,DB01118,Amiodarone
,22985658,AFT,"Before drug administration, LCx coronary artery stenosis lowered AFT from 25.2 ± 1.7 mA control (mean ± SEM) to 4.9 ± 1.0 mA baseline (P<.01).",Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22985658/),m,4.,155720,DB01118,Amiodarone
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB01118,Amiodarone
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB01118,Amiodarone
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB01118,Amiodarone
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB01118,Amiodarone
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB01118,Amiodarone
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB01118,Amiodarone
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB01118,Amiodarone
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB01118,Amiodarone
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB01118,Amiodarone
,20484171,trough concentration,Sirolimus concentrations obtained 3 days after initiation of dronedarone revealed a trough concentration that was increased by more than 3-fold (38.6 ng/mL) from his baseline trough concentration.,Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],38.6,168424,DB01118,Amiodarone
,20484171,trough concentration,"After sirolimus was held for 6 days, the trough concentration was 7.8 ng/mL.",Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],7.8,168425,DB01118,Amiodarone
,1981527,apparent plasma elimination half-life,The apparent plasma elimination half-life of amiodarone was prolonged following repeated drug administration (3.2 days) compared with a single drug dose (7.5 hr).,"Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981527/),d,3.2,168932,DB01118,Amiodarone
,1981527,apparent plasma elimination half-life,The apparent plasma elimination half-life of amiodarone was prolonged following repeated drug administration (3.2 days) compared with a single drug dose (7.5 hr).,"Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981527/),h,7.5,168933,DB01118,Amiodarone
,8877675,clearance,"The mean (% coefficient of variation, CV) value for clearance was 0.22 L/hr/kg (13%), central volume of distribution was 0.30 L/kg (11%), peripheral volume of distribution was 10.0 L/kg (9.5%), and intercompartmental clearance was 0.71 L/hr/kg (16%).",Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877675/),[l] / [h·kg],0.22,172991,DB01118,Amiodarone
,8877675,central volume of distribution,"The mean (% coefficient of variation, CV) value for clearance was 0.22 L/hr/kg (13%), central volume of distribution was 0.30 L/kg (11%), peripheral volume of distribution was 10.0 L/kg (9.5%), and intercompartmental clearance was 0.71 L/hr/kg (16%).",Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877675/),[l] / [kg],0.30,172992,DB01118,Amiodarone
,8877675,peripheral volume of distribution,"The mean (% coefficient of variation, CV) value for clearance was 0.22 L/hr/kg (13%), central volume of distribution was 0.30 L/kg (11%), peripheral volume of distribution was 10.0 L/kg (9.5%), and intercompartmental clearance was 0.71 L/hr/kg (16%).",Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877675/),[l] / [kg],10.0,172993,DB01118,Amiodarone
,8877675,intercompartmental clearance,"The mean (% coefficient of variation, CV) value for clearance was 0.22 L/hr/kg (13%), central volume of distribution was 0.30 L/kg (11%), peripheral volume of distribution was 10.0 L/kg (9.5%), and intercompartmental clearance was 0.71 L/hr/kg (16%).",Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877675/),[l] / [h·kg],0.71,172994,DB01118,Amiodarone
,10872646,volumes of distribution/bioavailability (V1/F,"Amiodarone concentrations were best described by a two-compartment model with the typical parameters +/- interindividual coefficients of variation (where applicable) as follows: volumes of distribution/bioavailability (V1/F = 882 L; V2/F = 12,700 L +/- 58%) and clearances/bioavailability (CL1/F = 229 L/day +/- 31%; and CL2/F = 599 L/day +/- 56%).",Population pharmacokinetics of long-term oral amiodarone therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872646/),l,882,174347,DB01118,Amiodarone
,10872646,V2/F,"Amiodarone concentrations were best described by a two-compartment model with the typical parameters +/- interindividual coefficients of variation (where applicable) as follows: volumes of distribution/bioavailability (V1/F = 882 L; V2/F = 12,700 L +/- 58%) and clearances/bioavailability (CL1/F = 229 L/day +/- 31%; and CL2/F = 599 L/day +/- 56%).",Population pharmacokinetics of long-term oral amiodarone therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872646/),l,"12,700",174348,DB01118,Amiodarone
,10872646,clearances/bioavailability (CL1/F,"Amiodarone concentrations were best described by a two-compartment model with the typical parameters +/- interindividual coefficients of variation (where applicable) as follows: volumes of distribution/bioavailability (V1/F = 882 L; V2/F = 12,700 L +/- 58%) and clearances/bioavailability (CL1/F = 229 L/day +/- 31%; and CL2/F = 599 L/day +/- 56%).",Population pharmacokinetics of long-term oral amiodarone therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872646/),[l] / [d],229,174349,DB01118,Amiodarone
,10872646,CL2/F,"Amiodarone concentrations were best described by a two-compartment model with the typical parameters +/- interindividual coefficients of variation (where applicable) as follows: volumes of distribution/bioavailability (V1/F = 882 L; V2/F = 12,700 L +/- 58%) and clearances/bioavailability (CL1/F = 229 L/day +/- 31%; and CL2/F = 599 L/day +/- 56%).",Population pharmacokinetics of long-term oral amiodarone therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872646/),[l] / [d],599,174350,DB01118,Amiodarone
,10872646,distribution half-life,"Rapid distribution half-life was 17 hours, and terminal half-life was 55 days.",Population pharmacokinetics of long-term oral amiodarone therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872646/),h,17,174351,DB01118,Amiodarone
,10872646,terminal half-life,"Rapid distribution half-life was 17 hours, and terminal half-life was 55 days.",Population pharmacokinetics of long-term oral amiodarone therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872646/),d,55,174352,DB01118,Amiodarone
,3242577,plasma protein binding,"2. The plasma protein binding of amiodarone was measured by erythrocyte partitioning, and found to be the same in six healthy subjects and eight patients being treated for cardiac arrhythmias (mean = 99.98%; range 99.97-99.99%).",Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242577/),%,99.98,174389,DB01118,Amiodarone
,11258173,absolute bioavailability,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),%,90,180720,DB01118,Amiodarone
,11258173,elimination half-life,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),h,12,180721,DB01118,Amiodarone
,2487521,peak plasma digoxin concentration,Mean (+/- SD) peak plasma digoxin concentration rose from 1.55 +/- 0.6 microgram /1 prior to amiodarone therapy to 2.85 +/- 1.3 micrograms/1 after 1 week of combined therapy (p less than 0.01).,The digoxin-amiodarone interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2487521/),μg,1.55,181885,DB01118,Amiodarone
,2487521,peak plasma digoxin concentration,Mean (+/- SD) peak plasma digoxin concentration rose from 1.55 +/- 0.6 microgram /1 prior to amiodarone therapy to 2.85 +/- 1.3 micrograms/1 after 1 week of combined therapy (p less than 0.01).,The digoxin-amiodarone interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2487521/),μg,2.85,181886,DB01118,Amiodarone
,2487521,AUC,Mean AUC also rose from 7.2 +/- 2.1 micrograms/1.h to 12.1 +/- 6.4 micrograms/1.h (p less than 0.01) during this period.,The digoxin-amiodarone interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2487521/),[μg] / [1·h],7.2,181887,DB01118,Amiodarone
,2487521,AUC,Mean AUC also rose from 7.2 +/- 2.1 micrograms/1.h to 12.1 +/- 6.4 micrograms/1.h (p less than 0.01) during this period.,The digoxin-amiodarone interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2487521/),[μg] / [1·h],12.1,181888,DB01118,Amiodarone
,1598834,flow rate,To increase life of the YWG-C18 column a mixture of methanol and 5 mmol.L-1 phosphate buffer (70:30 vol/vol) was selected as mobile phase with a flow rate of 0.8 ml.min-1.,[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ml] / [min],0.8,183331,DB01118,Amiodarone
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),%,95-102,183332,DB01118,Amiodarone
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ng] / [ml],10-1000,183333,DB01118,Amiodarone
,1598834,Vc,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg],6.3,183334,DB01118,Amiodarone
,1598834,Cl,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg·min],0.021,183335,DB01118,Amiodarone
,1598834,T1/2 alpha,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,30,183336,DB01118,Amiodarone
,1598834,T1/2 beta,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,230,183337,DB01118,Amiodarone
,1598834,AUC,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[min·μg] / [ml],102,183338,DB01118,Amiodarone
,7671898,heart rates,"The mean heart rates in the amiodarone group decreased significantly from 157 +/- 20 beats.min-1 to 122 +/- 25 beats.min-1 after 1 h (P < 0.05 vs baseline), and then decreased further to stabilize at 96 +/- 25 beats.min-1 after 6 h (P < 0.05).","Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671898/),[beats] / [min],157,184002,DB01118,Amiodarone
,7671898,heart rates,"The mean heart rates in the amiodarone group decreased significantly from 157 +/- 20 beats.min-1 to 122 +/- 25 beats.min-1 after 1 h (P < 0.05 vs baseline), and then decreased further to stabilize at 96 +/- 25 beats.min-1 after 6 h (P < 0.05).","Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671898/),[beats] / [min],122,184003,DB01118,Amiodarone
,7671898,heart rates,"The mean heart rates in the amiodarone group decreased significantly from 157 +/- 20 beats.min-1 to 122 +/- 25 beats.min-1 after 1 h (P < 0.05 vs baseline), and then decreased further to stabilize at 96 +/- 25 beats.min-1 after 6 h (P < 0.05).","Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7671898/),[beats] / [min],96,184004,DB01118,Amiodarone
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,90.8,189038,DB01118,Amiodarone
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,136,189039,DB01118,Amiodarone
,2438499,Bioavailability,Bioavailability derived from the mean values of oral and intravenous AUCs was 33% greater with amiodarone treatment.,Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2438499/),%,33,191975,DB01118,Amiodarone
,6175810,volume of distribution,"The pharmacokinetic parameters, calculated on the intravenous data using a two-compartment open model, indicate a very large volume of distribution (9.26-17.17 L/kg in healthy volunteers and 6.88-21.05 L/kg in patients).",Pharmacokinetics of amiodarone in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175810/),[l] / [kg],9.26-17.17,202483,DB01118,Amiodarone
,6175810,volume of distribution,"The pharmacokinetic parameters, calculated on the intravenous data using a two-compartment open model, indicate a very large volume of distribution (9.26-17.17 L/kg in healthy volunteers and 6.88-21.05 L/kg in patients).",Pharmacokinetics of amiodarone in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175810/),[l] / [kg],6.88-21.05,202484,DB01118,Amiodarone
,6175810,elimination half-life,The elimination half-life ranged from 12.09 to 20.70 h in volunteers and from 11.60 to 19.60 h in patients.,Pharmacokinetics of amiodarone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175810/),h,12.09 to 20.70,202485,DB01118,Amiodarone
,6175810,elimination half-life,The elimination half-life ranged from 12.09 to 20.70 h in volunteers and from 11.60 to 19.60 h in patients.,Pharmacokinetics of amiodarone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175810/),h,11.60 to 19.60,202486,DB01118,Amiodarone
,6175810,systemic bioavailability,"Oral absorption was slow an erratic, with fourfold individual variations in systemic bioavailability (22-86%).",Pharmacokinetics of amiodarone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6175810/),%,22-86,202487,DB01118,Amiodarone
,2422469,serum level,"Rats that received digoxin alone showed a serum level of 0.32 +/- 0.08 ng/ml, whereas those that received combination therapies showed a serum level of 3.25 +/- 1.06 ng/ml (p less than 0.001) with desethylamiodarone administration, and 3.00 +/- 0.87 ng/ml with amiodarone administration.",Digoxin-desethylamiodarone interaction in the rat: comparison with the effects of amiodarone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2422469/),[ng] / [ml],3.25,206465,DB01118,Amiodarone
,2422469,serum level,"Rats that received digoxin alone showed a serum level of 0.32 +/- 0.08 ng/ml, whereas those that received combination therapies showed a serum level of 3.25 +/- 1.06 ng/ml (p less than 0.001) with desethylamiodarone administration, and 3.00 +/- 0.87 ng/ml with amiodarone administration.",Digoxin-desethylamiodarone interaction in the rat: comparison with the effects of amiodarone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2422469/),[ng] / [ml],3.00,206466,DB01118,Amiodarone
,8891878,Ki,"Lidocaine inhibited amiodarone N-monodesethylation (Ki = 120 microM) competitively; inversely, amiodarone suppressed lidocaine N-monodesethylase activity in the same manner (Ki = 47 microM).",Interaction between amiodarone and lidocaine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891878/),μM,120,206607,DB01118,Amiodarone
,8891878,Ki,"Lidocaine inhibited amiodarone N-monodesethylation (Ki = 120 microM) competitively; inversely, amiodarone suppressed lidocaine N-monodesethylase activity in the same manner (Ki = 47 microM).",Interaction between amiodarone and lidocaine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891878/),μM,47,206608,DB01118,Amiodarone
,33924314,half-life,"There were no statistical differences in the area under the concentration time curve (6 h) or clearance, but there was a difference in the half-life between the two groups (3.12 vs. 0.85 h, p = 0.01).",Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33924314/),h,3.12,211143,DB01118,Amiodarone
,33924314,half-life,"There were no statistical differences in the area under the concentration time curve (6 h) or clearance, but there was a difference in the half-life between the two groups (3.12 vs. 0.85 h, p = 0.01).",Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33924314/),h,0.85,211144,DB01118,Amiodarone
,24271523,systemic clearance,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),[l] / [h·kg],0.057,211949,DB01118,Amiodarone
,24271523,systemic clearance,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),[l] / [h·kg],0.031,211950,DB01118,Amiodarone
,24271523,elimination half-life,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),h,2.03,211951,DB01118,Amiodarone
,24271523,elimination half-life,"In rats pretreated with amiodarone, a significant 45% reduction in the mean (± SD) systemic clearance [0.057 (0.010) vs 0.031 (0.004) liter/hr/kg, P < 0.001] and a greater than 100% increase in the mean elimination half-life [2.03 (0.46) vs 4.29 (0.71) hr, P < 0.001] of theophylline were observed.",The effect of amiodarone on theophylline pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24271523/),h,4.29,211952,DB01118,Amiodarone
,11420890,terminal half-life,The elimination of amiodarone from plasma after single dose followed a biphasic pattern with a terminal half-life of 54.7 +/- 8.2 hours.,Disposition of amiodarone in rats after single and multiple intra-peritoneal doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420890/),h,54.7,212619,DB01118,Amiodarone
,11420890,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 micrograms/ml, 1.73 micrograms/mg, 7.61 micrograms/mg and 29.01 micrograms/mg, respectively.",Disposition of amiodarone in rats after single and multiple intra-peritoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420890/),[μg] / [mg],1.73,212620,DB01118,Amiodarone
,11420890,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 micrograms/ml, 1.73 micrograms/mg, 7.61 micrograms/mg and 29.01 micrograms/mg, respectively.",Disposition of amiodarone in rats after single and multiple intra-peritoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420890/),[μg] / [mg],7.61,212621,DB01118,Amiodarone
,11420890,concentrations,"The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 micrograms/ml, 1.73 micrograms/mg, 7.61 micrograms/mg and 29.01 micrograms/mg, respectively.",Disposition of amiodarone in rats after single and multiple intra-peritoneal doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420890/),[μg] / [mg],29.01,212622,DB01118,Amiodarone
,28910187,Tmax,"The Tmax of amiodarone was significantly shorter in the SIO (99 secs) and IV (86 secs) groups compared to the TIO group (215 secs); P = 0.002 and P = 0.002, respectively.",Sternal Route More Effective than Tibial Route for Intraosseous Amiodarone Administration in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28910187/),secs,99,213859,DB01118,Amiodarone
,28910187,Tmax,"The Tmax of amiodarone was significantly shorter in the SIO (99 secs) and IV (86 secs) groups compared to the TIO group (215 secs); P = 0.002 and P = 0.002, respectively.",Sternal Route More Effective than Tibial Route for Intraosseous Amiodarone Administration in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28910187/),secs,86,213860,DB01118,Amiodarone
,28910187,Tmax,"The Tmax of amiodarone was significantly shorter in the SIO (99 secs) and IV (86 secs) groups compared to the TIO group (215 secs); P = 0.002 and P = 0.002, respectively.",Sternal Route More Effective than Tibial Route for Intraosseous Amiodarone Administration in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28910187/),secs,215,213861,DB01118,Amiodarone
,1284402,alpha,"When PA was given alone, the pharmacokinetic parameters alpha, beta, Kmo, K1m.V1.V-1m, were 0.20 +/- 0.04, 0.016 +/- 0.003, 0.027 +/- 0.01, and 0.043 +/- 0.02 min-1, respectively.",[Effects of amiodarone on kinetics of procainamide and its major metabolite disposition in rabbit]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1284402/),1/[min],0.20,213882,DB01118,Amiodarone
,1284402,V1.V-1m,"When PA was given alone, the pharmacokinetic parameters alpha, beta, Kmo, K1m.V1.V-1m, were 0.20 +/- 0.04, 0.016 +/- 0.003, 0.027 +/- 0.01, and 0.043 +/- 0.02 min-1, respectively.",[Effects of amiodarone on kinetics of procainamide and its major metabolite disposition in rabbit]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1284402/),1/[min],0.043,213883,DB01118,Amiodarone
,29435949,clearance (CL),"The empiric Bayesian estimates for clearance (CL), volume of distribution at steady state, and terminal half-life were 0.25 (90% CL 0.14-0.36) L/kg/h, 93 (68-174) L/kg, and 266 (197-477) h, respectively.",A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29435949/),[l] / [h·kg],0.25,214375,DB01118,Amiodarone
,29435949,volume of distribution at steady state,"The empiric Bayesian estimates for clearance (CL), volume of distribution at steady state, and terminal half-life were 0.25 (90% CL 0.14-0.36) L/kg/h, 93 (68-174) L/kg, and 266 (197-477) h, respectively.",A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29435949/),[l] / [kg],93,214376,DB01118,Amiodarone
,29435949,terminal half-life,"The empiric Bayesian estimates for clearance (CL), volume of distribution at steady state, and terminal half-life were 0.25 (90% CL 0.14-0.36) L/kg/h, 93 (68-174) L/kg, and 266 (197-477) h, respectively.",A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29435949/),h,266,214377,DB01118,Amiodarone
,3581646,plasma clearance,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg-hr],0.43,218219,DB01118,Amiodarone
,3581646,plasma clearance,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg-hr],0.33,218220,DB01118,Amiodarone
,3581646,plasma elimination half-life,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),h,3.77,218221,DB01118,Amiodarone
,3581646,plasma elimination half-life,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),h,5.21,218222,DB01118,Amiodarone
,3581646,volume of distribution,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg],2.31,218223,DB01118,Amiodarone
,3581646,volume of distribution,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg],2.47,218224,DB01118,Amiodarone
,8907716,t1/2beta,"DEA followed a biexponential decline with a t1/2beta of 54 center dot 8 and 46 center dot 2 h after the 20 and 40 mg kg-1 doses, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),center,54,218413,DB01118,Amiodarone
,8907716,t1/2beta,"DEA followed a biexponential decline with a t1/2beta of 54 center dot 8 and 46 center dot 2 h after the 20 and 40 mg kg-1 doses, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),h,8,218414,DB01118,Amiodarone
,8907716,t1/2beta,"DEA followed a biexponential decline with a t1/2beta of 54 center dot 8 and 46 center dot 2 h after the 20 and 40 mg kg-1 doses, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),h,46,218415,DB01118,Amiodarone
,8907716,Emax,"The mean (+/- SD) Emax for QT and T amplitude was 32 center dot 23 (+/- 2 center dot 47)% and 0 center dot 12(+/- 00 center dot 9) mV, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),%,32,218416,DB01118,Amiodarone
,8907716,Emax,"The mean (+/- SD) Emax for QT and T amplitude was 32 center dot 23 (+/- 2 center dot 47)% and 0 center dot 12(+/- 00 center dot 9) mV, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),%,23,218417,DB01118,Amiodarone
,8907716,Emax,"The mean (+/- SD) Emax for QT and T amplitude was 32 center dot 23 (+/- 2 center dot 47)% and 0 center dot 12(+/- 00 center dot 9) mV, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),mv,0,218418,DB01118,Amiodarone
,8907716,Emax,"The mean (+/- SD) Emax for QT and T amplitude was 32 center dot 23 (+/- 2 center dot 47)% and 0 center dot 12(+/- 00 center dot 9) mV, respectively.",Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),mv,12,218419,DB01118,Amiodarone
,8907716,EC50,The mean (+/- SD) EC50 value was 297 center dot 5 (+/- 22 center dot 80) ng ml-1 for QT and 139 center dot 8 (+/- 28 center dot 69) ng mL-1 for the T amplitude.,Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),[ng] / [ml],297,218420,DB01118,Amiodarone
,8907716,EC50,The mean (+/- SD) EC50 value was 297 center dot 5 (+/- 22 center dot 80) ng ml-1 for QT and 139 center dot 8 (+/- 28 center dot 69) ng mL-1 for the T amplitude.,Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),[ng] / [ml],5,218421,DB01118,Amiodarone
,8907716,EC50,The mean (+/- SD) EC50 value was 297 center dot 5 (+/- 22 center dot 80) ng ml-1 for QT and 139 center dot 8 (+/- 28 center dot 69) ng mL-1 for the T amplitude.,Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907716/),[ng] / [ml],139,218422,DB01118,Amiodarone
,3663881,terminal half-lives (t1/2 beta),"In all three groups, the blood 14C-amiodarone concentration-time curves declined bioexponentially with terminal half-lives (t1/2 beta) ranging from 14-22 hours.",Amiodarone pharmacokinetics. Disposition kinetics following subchronic administration in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663881/),h,14-22,218497,DB01118,Amiodarone
,3663881,clearance (CL),"In the rats pretreated with 100 mg kg-1 day-1 of amiodarone HCl for 5-6 weeks, amiodarone clearance (CL) and steady state volume of distribution (Vss) were reduced 52 per cent (12.2 to 5.9 ml min-1 kg-1) and 41 per cent (11.73 to 6.97 l kg-1), respectively.",Amiodarone pharmacokinetics. Disposition kinetics following subchronic administration in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663881/),%,52,218498,DB01118,Amiodarone
,3663881,steady state volume of distribution (Vss),"In the rats pretreated with 100 mg kg-1 day-1 of amiodarone HCl for 5-6 weeks, amiodarone clearance (CL) and steady state volume of distribution (Vss) were reduced 52 per cent (12.2 to 5.9 ml min-1 kg-1) and 41 per cent (11.73 to 6.97 l kg-1), respectively.",Amiodarone pharmacokinetics. Disposition kinetics following subchronic administration in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663881/),%,41,218499,DB01118,Amiodarone
,2886599,plasma concentrations,Amiodarone plasma concentrations ranged from 0.74 to 4.68 micrograms mL-1 and desethylamiodarone from 0.08 to 2.05 micrograms mL-1.,Amiodarone and desethylamiodarone tissue uptake in rats chronically treated with amiodarone is non-linear with the dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886599/),[μg] / [ml],0.74 to 4.68,223414,DB01118,Amiodarone
,2886599,plasma concentrations,Amiodarone plasma concentrations ranged from 0.74 to 4.68 micrograms mL-1 and desethylamiodarone from 0.08 to 2.05 micrograms mL-1.,Amiodarone and desethylamiodarone tissue uptake in rats chronically treated with amiodarone is non-linear with the dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886599/),,0.08 to 2.05,223415,DB01118,Amiodarone
,12784322,beta half-life,"Observed simulations were done using a two-compartment model with a beta half-life of 100 h, sampling to 200 and 300 h, followed by 1 to 4 washout half-lives.","Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalence. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784322/),h,100,223619,DB01118,Amiodarone
,30845890,trough level,A therapeutic tacrolimus concentration was defined as a trough level between 8 and 15 ng/mL for 2 consecutive days.,Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30845890/),[ng] / [ml],8 and 15,228865,DB01118,Amiodarone
,1753010,bioavailable,Amiodarone is poorly bioavailable (20-80%) and undergoes extensive enterohepatic circulation before entry into a central compartment.,Pharmacology and pharmacokinetics of amiodarone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1753010/),%,20-80,230324,DB01118,Amiodarone
,1753010,distribution half-life,The distribution half-life of amiodarone out of the central compartment to peripheral and deep tissue compartments (t1/2 alpha) may be as short as 4 hours.,Pharmacology and pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1753010/),h,4,230325,DB01118,Amiodarone
,1753010,t1/2 alpha),The distribution half-life of amiodarone out of the central compartment to peripheral and deep tissue compartments (t1/2 alpha) may be as short as 4 hours.,Pharmacology and pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1753010/),h,4,230326,DB01118,Amiodarone
,1753010,terminal half-life (t1/2 beta),The terminal half-life (t1/2 beta) is both long and variable (9-77 days) secondary to the slow mobilization of the lipophilic medication out of (primarily) adipocytes.,Pharmacology and pharmacokinetics of amiodarone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1753010/),d,9-77,230327,DB01118,Amiodarone
,2867194,Total body clearance,"Total body clearance of digoxin was 138.84 +/- 44.67 and 147.99 +/- 29.17 ml min-1, serum half life 187.9 +/- 60.9 and 181.34 +/- 25.57 min and volume of distribution 35.4 +/- 8.54 and 37.8 +/- 3.9 litres before and after amiodarone treatment, respectively.",Amiodarone does not affect digoxin kinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867194/),[ml] / [min],138.84,236340,DB01118,Amiodarone
,2867194,Total body clearance,"Total body clearance of digoxin was 138.84 +/- 44.67 and 147.99 +/- 29.17 ml min-1, serum half life 187.9 +/- 60.9 and 181.34 +/- 25.57 min and volume of distribution 35.4 +/- 8.54 and 37.8 +/- 3.9 litres before and after amiodarone treatment, respectively.",Amiodarone does not affect digoxin kinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867194/),[ml] / [min],147.99,236341,DB01118,Amiodarone
,2867194,serum half life,"Total body clearance of digoxin was 138.84 +/- 44.67 and 147.99 +/- 29.17 ml min-1, serum half life 187.9 +/- 60.9 and 181.34 +/- 25.57 min and volume of distribution 35.4 +/- 8.54 and 37.8 +/- 3.9 litres before and after amiodarone treatment, respectively.",Amiodarone does not affect digoxin kinetics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867194/),min,187.9,236342,DB01118,Amiodarone
,2867194,serum half life,"Total body clearance of digoxin was 138.84 +/- 44.67 and 147.99 +/- 29.17 ml min-1, serum half life 187.9 +/- 60.9 and 181.34 +/- 25.57 min and volume of distribution 35.4 +/- 8.54 and 37.8 +/- 3.9 litres before and after amiodarone treatment, respectively.",Amiodarone does not affect digoxin kinetics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867194/),min,181.34,236343,DB01118,Amiodarone
,2867194,volume of distribution,"Total body clearance of digoxin was 138.84 +/- 44.67 and 147.99 +/- 29.17 ml min-1, serum half life 187.9 +/- 60.9 and 181.34 +/- 25.57 min and volume of distribution 35.4 +/- 8.54 and 37.8 +/- 3.9 litres before and after amiodarone treatment, respectively.",Amiodarone does not affect digoxin kinetics in the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867194/),l,35.4,236344,DB01118,Amiodarone
,2867194,volume of distribution,"Total body clearance of digoxin was 138.84 +/- 44.67 and 147.99 +/- 29.17 ml min-1, serum half life 187.9 +/- 60.9 and 181.34 +/- 25.57 min and volume of distribution 35.4 +/- 8.54 and 37.8 +/- 3.9 litres before and after amiodarone treatment, respectively.",Amiodarone does not affect digoxin kinetics in the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867194/),l,37.8,236345,DB01118,Amiodarone
,3958923,total clearance of 1,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),[l] / [h·kg],1.74,238706,DB01118,Amiodarone
,3958923,total clearance of 1,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),[l] / [h·kg],0.35,238707,DB01118,Amiodarone
,3958923,volume of distribution at steady state,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),[l] / [kg],21.1,238708,DB01118,Amiodarone
,3958923,volume of distribution at steady state,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),[l] / [kg],5.0,238709,DB01118,Amiodarone
,3958923,total clearance,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),[l] / [h·kg],1.67,238710,DB01118,Amiodarone
,3958923,total clearance,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),[l] / [h·kg],0.9,238711,DB01118,Amiodarone
,3958923,apparent elimination half-life,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),h,13.7,238712,DB01118,Amiodarone
,3958923,apparent elimination half-life,"Compared with controls, biliary stasis caused a decrease in the total clearance of 1 (1.74 versus 0.35 L/h/kg) and in the volume of distribution at steady state (21.1 versus 5.0 L/kg); renal failure caused a decrease in total clearance (1.67 versus 0.9 L/h/kg) and an increase in apparent elimination half-life (13.7 versus 10.1 h).",Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958923/),h,10.1,238713,DB01118,Amiodarone
,12398559,steady-state plasma concentrations,The mean steady-state plasma concentrations of amiodarone were not significantly different for Cordarone compared with Pacerone (1.07 +/- 0.48 vs.,Comparison of plasma concentrations for two amiodarone products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12398559/),,1.07,240761,DB01118,Amiodarone
,2743707,Serum AUC,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[h·mg] / [l],245,241153,DB01118,Amiodarone
,2743707,Serum AUC,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[h·mg] / [l],342,241154,DB01118,Amiodarone
,2743707,area under the first moment curve,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[hr2·mg] / [l],5666,241155,DB01118,Amiodarone
,2743707,area under the first moment curve,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[hr2·mg] / [l],"11,632",241156,DB01118,Amiodarone
,2743707,total body clearance,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[l] / [h],1.57,241157,DB01118,Amiodarone
,2743707,total body clearance,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),[l] / [h],1.17,241158,DB01118,Amiodarone
,2743707,apparent elimination half-life,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),h,16.1,241159,DB01118,Amiodarone
,2743707,apparent elimination half-life,"Serum AUC increased from 245 +/- 37.6 to 342 +/- 87.3 mg.hr/L (p = 0.007); area under the first moment curve increased from 5666 +/- 1003 to 11,632 +/- 4198 mg.hr2/L (p = 0.008); the time-averaged total body clearance decreased from 1.57 +/- 0.3 to 1.17 +/- 0.33 L/hr (p = 0.0004); and the apparent elimination half-life increased from 16.1 +/- 1.32 to 22.6 +/- 3.8 hours (p = 0.001) for phenytoin during phase II.",Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743707/),h,22.6,241160,DB01118,Amiodarone
,6540111,terminal half-life (t1/2),"The decline in amiodarone plasma concentration after a single intravenous 400 mg dose was described by a triexponential decay equation, with a mean terminal half-life (t1/2) of 34.5 h.",Pharmacokinetics and body distribution of amiodarone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540111/),h,34.5,241872,DB01118,Amiodarone
,6540111,clearance,Mean values for clearance and apparent volume of distribution were 14.7 +/- 7.2 l/h and 376 +/- 372 l.,Pharmacokinetics and body distribution of amiodarone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540111/),[l] / [h],14.7,241873,DB01118,Amiodarone
,6540111,apparent volume of distribution,Mean values for clearance and apparent volume of distribution were 14.7 +/- 7.2 l/h and 376 +/- 372 l.,Pharmacokinetics and body distribution of amiodarone in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540111/),l,376,241874,DB01118,Amiodarone
,6540111,terminal half-life,The mean terminal half-life for amiodarone after oral dosage was 31.6 +/- 21.3 h.,Pharmacokinetics and body distribution of amiodarone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540111/),h,31.6,241875,DB01118,Amiodarone
,6540111,peak concentrations,Amiodarone peak concentrations of 0.37 +/- 0.22 micrograms/ml were attained in 4.8 +/- 1.5 h.,Pharmacokinetics and body distribution of amiodarone in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540111/),[μg] / [ml],0.37,241876,DB01118,Amiodarone
,6540111,bioavailability,"The bioavailability of oral amiodarone was only 31 +/- 26%, in part due to first-pass metabolism.",Pharmacokinetics and body distribution of amiodarone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540111/),%,31,241877,DB01118,Amiodarone
,8525224,Cmax,After oral administration a Cmax of 1.17 +/- 0.3 mg/ml was achieved at 3.25 +/- 0.46 h (tmax).,[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),[mg] / [ml],1.17,242470,DB01118,Amiodarone
,8525224,tmax,After oral administration a Cmax of 1.17 +/- 0.3 mg/ml was achieved at 3.25 +/- 0.46 h (tmax).,[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),h,3.25,242471,DB01118,Amiodarone
,8525224,Absolute bioavailability,Absolute bioavailability ranged from 50.4 to 87.8% (68.6 +/- 12.6%).,[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),%,50.4 to 87.8,242472,DB01118,Amiodarone
,8525224,Absolute bioavailability,Absolute bioavailability ranged from 50.4 to 87.8% (68.6 +/- 12.6%).,[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),%,68.6,242473,DB01118,Amiodarone
,8525224,half life,"After intravenous administration, Amiodarone had a half life of 7.53 +/- 0.96 h, a total body clearance of 4.25 +/- 0.73 ml/kg/min and a distribution volume of 2.99 +/- 0.71 l/kg.",[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),h,7.53,242474,DB01118,Amiodarone
,8525224,total body clearance,"After intravenous administration, Amiodarone had a half life of 7.53 +/- 0.96 h, a total body clearance of 4.25 +/- 0.73 ml/kg/min and a distribution volume of 2.99 +/- 0.71 l/kg.",[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),[ml] / [kg·min],4.25,242475,DB01118,Amiodarone
,8525224,distribution volume,"After intravenous administration, Amiodarone had a half life of 7.53 +/- 0.96 h, a total body clearance of 4.25 +/- 0.73 ml/kg/min and a distribution volume of 2.99 +/- 0.71 l/kg.",[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525224/),[l] / [kg],2.99,242476,DB01118,Amiodarone
,9568214,Peak concentrations,Peak concentrations of amiodarone in both serum (3.60 +/- 1.02 micrograms/ml) and tissue (84.2 +/- 6.50 ng/mg) occurred within 5 minutes of drug administration.,Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9568214/),[μg] / [ml],3.60,242510,DB01118,Amiodarone
,9568214,Peak concentrations,Peak concentrations of amiodarone in both serum (3.60 +/- 1.02 micrograms/ml) and tissue (84.2 +/- 6.50 ng/mg) occurred within 5 minutes of drug administration.,Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9568214/),[ng] / [mg],84.2,242511,DB01118,Amiodarone
,9568214,volume of distribution (VD),"As reported by others, this study demonstrated that the volume of distribution (VD) of amiodarone was large (33.31 +/- 35.21 L/kg), and the clearance (Cl) was low (13.6 +/- 4.4 ml/min/kg).",Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9568214/),[l] / [kg],33.31,242512,DB01118,Amiodarone
,9568214,clearance (Cl),"As reported by others, this study demonstrated that the volume of distribution (VD) of amiodarone was large (33.31 +/- 35.21 L/kg), and the clearance (Cl) was low (13.6 +/- 4.4 ml/min/kg).",Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9568214/),[ml] / [kg·min],13.6,242513,DB01118,Amiodarone
,9568214,serum t1/2,Marked prolongation of both the serum t1/2 (29.98 +/- 29.26 hours) and the myocardial t1/2 (29.20 +/- 29.49 hours) were noted as well.,Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9568214/),h,29.98,242514,DB01118,Amiodarone
,9568214,t1/2,Marked prolongation of both the serum t1/2 (29.98 +/- 29.26 hours) and the myocardial t1/2 (29.20 +/- 29.49 hours) were noted as well.,Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9568214/),h,29.20,242515,DB01118,Amiodarone
less,11737993,run time,Analytical run time was less than 13 min.,High-performance liquid chromatography assay of amiodarone in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737993/),min,13,244507,DB01118,Amiodarone
,11737993,recovery,"Mean recovery was 75% and 82% for lower (0.5 microg/ml) and higher concentrations (5 microg/ml), respectively.",High-performance liquid chromatography assay of amiodarone in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737993/),%,75,244508,DB01118,Amiodarone
,11737993,recovery,"Mean recovery was 75% and 82% for lower (0.5 microg/ml) and higher concentrations (5 microg/ml), respectively.",High-performance liquid chromatography assay of amiodarone in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737993/),%,82,244509,DB01118,Amiodarone
,25165788,total analytical run time,The total analytical run time was 20 min.,Pharmacokinetics of dronedarone in rat using a newly developed high-performance liquid chromatographic assay method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165788/),min,20,244992,DB01118,Amiodarone
>,25165788,recovery,"Mean recovery was >80%; the assay had excellent linear relationships (>0.999) between peak height ratios and plasma concentrations; the lower limit of quantification 25 was ng/mL, based on 100 μL of rat plasma.",Pharmacokinetics of dronedarone in rat using a newly developed high-performance liquid chromatographic assay method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165788/),%,80,244993,DB01118,Amiodarone
,1692941,concentrations,Plasma desethylamiodarone concentrations were in the range of 0.2 +/- 0.1 to 0.4 +/- 0.2 microgram/ml from weeks 1 through 8.,Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1692941/),,0.2,245611,DB01118,Amiodarone
,1692941,concentrations,Plasma desethylamiodarone concentrations were in the range of 0.2 +/- 0.1 to 0.4 +/- 0.2 microgram/ml from weeks 1 through 8.,Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1692941/),,0,245612,DB01118,Amiodarone
,27868228,clearance,"Analysis of two blood samples taken 9 and 10 days after docetaxel revealed plasma levels of 4.73 and 4.09 ng ml-1 , respectively, leading to a 79% decreased individual (Bayesian maximum a posteriori) clearance estimate of 9.15 l h-1 , corresponding to an estimated fivefold increase in AUC.",Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27868228/),[l] / [h],9.15,254796,DB01118,Amiodarone
,27194397,plasma clearance,"After intravenous doses of 4 mg/kg dronedarone, plasma clearance and volume of distribution at steady-state were 25.1 ± 8.09 mL/min/kg and 10.8 ± 4.77 L/kg, respectively.",The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194397/),[ml] / [kg·min],25.1,256225,DB01118,Amiodarone
,27194397,volume of distribution at steady-state,"After intravenous doses of 4 mg/kg dronedarone, plasma clearance and volume of distribution at steady-state were 25.1 ± 8.09 mL/min/kg and 10.8 ± 4.77 L/kg, respectively.",The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194397/),[l] / [kg],10.8,256226,DB01118,Amiodarone
,27194397,maximum plasma concentrations (Cmax),"After oral doses the maximum plasma concentrations (Cmax) and their median time of attainment (tmax) were 1.87 ± 1.65 mg/mL and 3.5 h, respectively.",The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194397/),[mg] / [ml],1.87,256227,DB01118,Amiodarone
,27194397,time of attainment (tmax),"After oral doses the maximum plasma concentrations (Cmax) and their median time of attainment (tmax) were 1.87 ± 1.65 mg/mL and 3.5 h, respectively.",The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194397/),h,3.5,256228,DB01118,Amiodarone
,27194397,tmax,"Intraperitoneal administration of 65 mg/kg dronedarone base yielded plasma Cmax and median tmax of 0.816 ± 0.611 mg/mL and 3 h, respectively.",The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194397/),h,3,256229,DB01118,Amiodarone
<,27194397,bioavailability,The drug showed poor bioavailability (<20%) after oral and intraperitoneal administration.,The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194397/),%,20,256230,DB01118,Amiodarone
,24051016,QTc intervals,"Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively.",Pharmacokinetics of intravenous amiodarone in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24051016/),ms,443,260276,DB01118,Amiodarone
,24051016,QTc intervals,"Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively.",Pharmacokinetics of intravenous amiodarone in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24051016/),ms,458,260277,DB01118,Amiodarone
,24051016,QTc intervals,"Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively.",Pharmacokinetics of intravenous amiodarone in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24051016/),ms,467,260278,DB01118,Amiodarone
,29962267,oral bioavailability,"The oral bioavailability of dronedarone was evaluated as approximately 16% in rats, similar to that in humans.",Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29962267/),%,16,261968,DB01118,Amiodarone
,4078704,level,"In skeletal muscle, the level of 1 was 22.50 +/- 14.7 ng/g without 2, 41.00 +/- 2.45 ng/g (p less than 0.05) after a low dose, and 77.60 +/- 17.45 ng/g (p less than 0.05) after a high dose.",Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4078704/),[ng] / [g],22.50,262792,DB01118,Amiodarone
,4078704,level,"In skeletal muscle, the level of 1 was 22.50 +/- 14.7 ng/g without 2, 41.00 +/- 2.45 ng/g (p less than 0.05) after a low dose, and 77.60 +/- 17.45 ng/g (p less than 0.05) after a high dose.",Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4078704/),[ng] / [g],41.00,262793,DB01118,Amiodarone
,4078704,level,"In skeletal muscle, the level of 1 was 22.50 +/- 14.7 ng/g without 2, 41.00 +/- 2.45 ng/g (p less than 0.05) after a low dose, and 77.60 +/- 17.45 ng/g (p less than 0.05) after a high dose.",Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4078704/),[ng] / [g],77.60,262794,DB01118,Amiodarone
,4078704,1,"In skeletal muscle, the level of 1 was 22.50 +/- 14.7 ng/g without 2, 41.00 +/- 2.45 ng/g (p less than 0.05) after a low dose, and 77.60 +/- 17.45 ng/g (p less than 0.05) after a high dose.",Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4078704/),[ng] / [g],22.50,262795,DB01118,Amiodarone
,4078704,1,"In skeletal muscle, the level of 1 was 22.50 +/- 14.7 ng/g without 2, 41.00 +/- 2.45 ng/g (p less than 0.05) after a low dose, and 77.60 +/- 17.45 ng/g (p less than 0.05) after a high dose.",Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4078704/),[ng] / [g],41.00,262796,DB01118,Amiodarone
,4078704,1,"In skeletal muscle, the level of 1 was 22.50 +/- 14.7 ng/g without 2, 41.00 +/- 2.45 ng/g (p less than 0.05) after a low dose, and 77.60 +/- 17.45 ng/g (p less than 0.05) after a high dose.",Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4078704/),[ng] / [g],77.60,262797,DB01118,Amiodarone
,33606068,AUCs,"The AUCs in the in vitro brain cell culture after 14-day repeated dosing of nominal concentration equal to 1.25 and 2.5 µM amiodarone were 1.00 and 1.99 µg*h/mL, respectively.",Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33606068/),[h·μg] / [ml],1.00,267793,DB01118,Amiodarone
,33606068,AUCs,"The AUCs in the in vitro brain cell culture after 14-day repeated dosing of nominal concentration equal to 1.25 and 2.5 µM amiodarone were 1.00 and 1.99 µg*h/mL, respectively.",Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33606068/),[h·μg] / [ml],1.99,267794,DB01118,Amiodarone
,33606068,bioavailability factor,The BMDU was 385.4 mg for intravenous converted to 593 mg for oral application using the bioavailability factor of 0.65 as reported in the literature.,Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33606068/),,0.65,267795,DB01118,Amiodarone
,6745303,plasma clearance rate,The observed plasma clearance rate for the drug varied from 0.2 to 0.5 1.h-1.kg-1 of body weight; and the elimination half-life of the unchanged compound was found to be approximately 21 hours.,Mass spectrometric identification of amiodarone N-monodesethyl metabolite and application of an HPLC method to a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745303/),[1] / [h·kg],0.2 to 0.5,268374,DB01118,Amiodarone
,6745303,elimination half-life,The observed plasma clearance rate for the drug varied from 0.2 to 0.5 1.h-1.kg-1 of body weight; and the elimination half-life of the unchanged compound was found to be approximately 21 hours.,Mass spectrometric identification of amiodarone N-monodesethyl metabolite and application of an HPLC method to a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745303/),h,21,268375,DB01118,Amiodarone
,6745303,Oral bioavailability,"Oral bioavailability, as determined in one patient, was about 60%.",Mass spectrometric identification of amiodarone N-monodesethyl metabolite and application of an HPLC method to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745303/),%,60,268376,DB01118,Amiodarone
,3558577,elimination half-life,The elimination half-life (5.8 h) of AM after a 5 mg/kg intravenous dose to a patient was similar to that after acute oral doses.,Sensitive method for the measurement of amiodarone and desethylamiodarone in serum and tissue and its application to disposition studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3558577/),h,5.8,269852,DB01118,Amiodarone
greater,2712399,overall recovery,The mean overall recovery from plasma samples was greater than 90 p. cent for both compounds.,High performance liquid chromatographic method for routine monitoring of amiodarone and desethylamiodarone plasma levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712399/),cent·p,90,270271,DB01118,Amiodarone
,3392238,time from,"In retrospect, the time from the initiation of amiodarone to the initial documentation of worsening ranged from 1 to 23 days (mean +/- SD, 9.4 +/- 8.2 days) and the time from the initiation of therapy to the recognition of worsening ranged from 6 to 26 days (14.6 +/- 10.1 days).",Worsening of ventricular tachycardia by amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392238/),d,6 to 26,270455,DB01118,Amiodarone
,3392238,time from,"In retrospect, the time from the initiation of amiodarone to the initial documentation of worsening ranged from 1 to 23 days (mean +/- SD, 9.4 +/- 8.2 days) and the time from the initiation of therapy to the recognition of worsening ranged from 6 to 26 days (14.6 +/- 10.1 days).",Worsening of ventricular tachycardia by amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392238/),d,14.6,270456,DB01118,Amiodarone
,3850764,t1/2 beta,"Plasma pharmacokinetic profile was determined and the calculated t1/2 beta of 3.5 +/- 2.8 and 3.2 +/- 0.6 hour after 5 or 40 mg/Kg dose, respectively, were obtained.","Pharmacokinetics, antiarrhythmic effects, and tissue concentrations of amiodarone and desethylamiodarone in dogs with acute coronary artery occlusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3850764/),h,3.5,272510,DB01118,Amiodarone
,3850764,t1/2 beta,"Plasma pharmacokinetic profile was determined and the calculated t1/2 beta of 3.5 +/- 2.8 and 3.2 +/- 0.6 hour after 5 or 40 mg/Kg dose, respectively, were obtained.","Pharmacokinetics, antiarrhythmic effects, and tissue concentrations of amiodarone and desethylamiodarone in dogs with acute coronary artery occlusion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3850764/),h,3.2,272511,DB01118,Amiodarone
